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ABSTRACT 
Pharmaceuticals are biologically active and persistent substances which have been recognized as a con- tinuing threat to environmental stability. Chronic ecotoxicity 
data as well as information on the current distribution levels in different environmental compartments continue to be sparse and are focused on those therapeutic 
classes that are more frequently prescribed and consumed. Nevertheless, they indicate the negative impact that these chemical contaminants may have on living 
organisms, ecosystems and ultimately, public health. This article reviews the different contamination sources as well as fate and both acute and chronic effects on non-
target organisms. An extensive review of existing data in the form of tables, encompassing many therapeutic classes is presented. 
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Fig. 1. Percentage of published studies on different therapeutic classes, expressed in relative percentage, described on 183 articles published between 1996 and 2009. 
 
 
 
 
1. Introduction 
 
The presence of medicines in the environment has become a recent 
research topic. Initially, the problem was highlighted in the US back 
in the 1970s [1,2] and almost a decade later in Eng- land (UK) [3–5]. 
Yet, it was only in the mid 90s with advances in analytical techniques 
that important knowledge on environmental contamination by those 
compounds grew. Powerful hyphenated chromatographic-detection 
techniques enabling detection limits within the ng L−1 to µg L−1 range 
allowed researchers to quantify a large number of medicines components 
(i.e. drugs and excipients) in the environment, thus compelling the 
scientific community to consider this contamination type as a potential 
issue meriting con- cern [6–8]. In fact, tons of them are produced 
annually worldwide to be consumed by humans or animals [9,10]. They 
are conceived primarily to have particular physiological modes of action 
and fre- quently to resist to inactivation before exerting their 
intended therapeutic effect. However, these same properties are 
paradox- ically responsible either for bioaccumulation and toxic effects 
in aquatic and terrestrial ecosystems [10,11]. In a different way from 
some conventional pollutants (such as pesticides, detergents, fuels, 
among others), medicines are continuously delivered at low levels which 
might give rise to toxicity even without high persistence rates [11–13]. 
Wide dissemination at low concentrations mainly in the aquatic 
environment is evident today. Such concentrations have been detected in 
aquatic compartments such as influents [14–16] and effluents [17–19] 
from sewage treatment plants (STPs), surface waters (rivers, lakes, 
streams, estuaries, among others) [20–24], seawater [25], groundwater 
[26–28] and drinking water [29–32]. The scientific community is in 
broad agreement with the possibility that adverse effects may arise from 
the presence of pharmaceu- ticals not only for human health but also 
for aquatic organisms. Several, almost negligible effects have been 
shown to occur from continuous exposure during the life cycle of 
aquatic vertebrates and invertebrates to sub-therapeutic drug 
concentrations [33,34]. These effects slowly accumulate to manifest 
themselves into a final irreversible condition which is frequently only 
noticed sev- eral generations’ later, affecting sustainability of aquatic 
organisms’ populations [35]. 
This review presents an updated survey of the acquired knowl- edge 
regarding the sources, spreading conditions, occurrence and induced 
toxic effects on non-target organisms by drugs in the envi- ronment. Fig. 
1 illustrates the clear predominance of studies on non-steroidal anti-
inflammatory drugs (NSAIDs), antibiotics and 
 
 
 
 
Fig. 2. Schematic representation of pharmaceutical biotransformation to increase their 
polarity (adapted from Reference [35]). 
 
blood lipid lowering agents from the literature, drawn from human 
prescription and consumption. Most of the reported data concerns the 
occurrence of drugs of each therapeutic class in the aquatic 
environment and is included in the form of tables to facilitate easy 
comparison between regional sample sources and ecotoxicologi- cal 
data. Current EU and US legislation compels new medicines to undergo 
an environmental impact assessment and consequently, new evaluation 
methods for acute as well as chronic effects are being implemented. 
However, a significant lack of knowledge per- sists particularly 
concerning toxicological data from synergistic pharmaceuticals 
interactions. 
 
2. Sources of environmental contamination 
 
The most obvious pathway for environmental contamination of 
medicines is via the unaltered excretion in urine and faeces although 
other anthropogenic mechanisms should be assumed, namely: 
 
a) Metabolism post-consumption; since many drugs are metabolised 
as the organism attempts to convert hydrophobic compounds into 
more easily excreted polar residues. Their bio- conversion into one or 
more metabolites can occur throughout Phase I1 and Phase II2 
reactions as shown in Fig. 2 [36]. 
b) Diagnostic compounds; such as X-ray contrast media are directly 
discharged in their native forms. 
c) Household Disposal; either topic formulations or unused medicines 
(out-of-date or unwanted) are discarded through the sink/toilet or via 
waste collection [9,37,38], before being taken to 
 
 
 
1 Phase I reactions include oxidation, reduction and hydrolysis to modify the orig- inal 
molecule structure by introducing functional groups more receptive to phase II reactions. 
2   Phase II reactions (or conjugation reactions) consist of the addition of  endoge- 
nous groups (like glucuronic acid, sulphate, glutathione, etc.) to receptive functional groups 
present in the original molecule or in its metabolite derived from phase I. 
  
 
Fig. 3. Representative sources and fate of pharmaceuticals in the environment (adapted 
from Reference [6]). 
 
 
landfill sites where they appear as terrestrial ecosystem contam- 
inants. Alternatively, they may possibly leak into surrounding water 
compartments [39,40]. 
d) Impacts due to anthropogenic activities; as, for instance, Sewage 
Treatment Plant (STP) sludge, which can carry non-suspected drugs 
and is frequently used as a fertilizer on agricultural land 
[41,42]; veterinary medicines, which are also excreted in urine and 
faeces by animals before being spread onto land via manure 
application as fertilisers. Apart from the potential for direct soil 
contamination, there is also the risk of run-off with heavy rain, thus 
potentially contaminating both the surround- ing surface and 
groundwater [42–44]. Other example of an anthropogenic activity 
is aquaculture, whose pharmaceuticals employed, as well as their 
metabolites and degradation prod- ucts, are directly discharged into 
surface waters [45,46]. Another important source of environmental 
contamination by pharma- ceuticals is the effluents of 
pharmaceutical production facilities [47–49]. 
 
At a higher level, existing geographical information on environ- 
mental contamination sources is sparse and limited. Countries and 
regions worldwide differ concerning the prevalence of diseases, waste 
treatment processes, cultural habits or economic constraints related to 
the pharmaceutical market [8]. Nevertheless, it seems that urban 
regions are major sources of contamination due to the proximity of 
hospitals and STP facilities. Additionally, the contri- bution of rural 
regions where agriculture, animal husbandry and aquaculture represent 
important ways of life should be considered as important. 
 
3. Environmental fate 
 
The fate and behaviour of medicines in the environment still 
requires further elucidation. As previously stated, drugs (used in human 
and/or in veterinary medicine) and their metabolites are spread into the 
environment in different ways,  namely through STP effluents, heavy 
rain on agricultural land provokes (surface) water run-off, and 
occasionally, through untreated sewage (domes- tic wastes and flooding, 
among others) (Fig. 3). Some of them do reach surface waters (rivers, 
lakes and estuaries, among others) and eventually groundwaters [11,35,39] 
after resisting the intended biological degradation. However, in surface 
waters they may be degraded  through  different  processes  such  as  
photolysis  whose 
 
efficiency depends on factors such as intensity of solar irradiation, 
latitude, season of the year and presence of photosensitizes (e.g. 
nitrates, humic acids) [50,51]. 
In the case of drugs that have low volatility and high polarity 
distribution is mainly made by aqueous transport or even via food chain 
dispersion [35,52]. Usually, wastewaters are conducted to STPs, which 
play a key role in the entrance of pharmaceuticals in the environment. 
However, in some regions or even countries these kinds of facilities may 
not exist and the environmental problem is still worse. The evaluation 
of removal efficiency in STPs (by com- paring influent and effluent 
contents) has been studied in detail, showing removal rates that can 
differ by up to 99% [22,53–55]. Depending both on the particular 
technology resorted to and the active substance properties they may 
undergo: (i) degradation (mineralization) to low molecular weight 
compounds (e.g. CO2 and water); (ii) entrapment by suspended solids; 
(iii) discharge of the parent compound through chemical cleavage of the 
respective con- jugate forms and (iv) conversion to a more hydrophilic, 
persistent form which will short-circuit the treatment process 
[39,41,56,57]. Thus, in hospitals use of specific antibiotics, 
antineoplasic or diag- nostic agents subsequently requires a sewage 
treatment process more embracing and directed to these kind of drugs, 
which are only used in hospitals [35,58], and that must be different 
to the more specific procedure adopted at STPs receiving industrial dis- 
charges from drug manufactures [47–49,59]. In both, the form and 
extension of the final contamination risk will also depend on geo- 
graphical location of the STP facility. Low adsorption coefficients that 
make active substances remain in the aqueous phase, favour their 
mobility through the STP and into nearby surface waters [53]. 
Adsorption to suspended solids depending on both hydropho- bic and 
electrostatic interactions established between each will follow the 
same destiny [11,41]. On the other hand, hydropho- bic metabolites 
will be held on STP sludge, provoking terrestrial contamination, thus 
affecting microorganisms and invertebrates. Aerobic/anaerobic bio-
conversion occurring either during sewage sludge digestion or during 
activated sludge treatment seems to be the most efficient process to 
eliminate chemical contaminants from the aquatic environment. 
Usually, the best biodegradation results are obtained when activated 
sludge treatment is conducted through an increase in hydraulic 
retention time and the use of mature sludge [10]. However, one should 
be aware of the fact that if a particular pharmaceutical is not detected in a 
STP effluent, this does not imply that it has been fully removed. On some 
occasions, it may have been degraded and give rise to unsuspecting 
metabo- lites that will subsequently contaminate surface waters 
[35,39,60]. Notwithstanding that some drugs and their metabolites 
show a stable nature, nowadays is still difficult to establish a 
complete contamination pattern in final receiving surface waters, due to 
the water dilution, the treatment and discharging processes [54]. 
 
 
4. Ecotoxicology 
 
Continuous consumption of drugs even at sub-therapeutic con- 
centrations represents a potential threat to public health although one 
should bear in mind that it is still impossible to evaluate the effects of 
exposure on human health [35,60,61]. In turn, many non-target 
organisms (which possess human- and animal-alike metabolic 
pathways, similar receptors or biomolecules) are there- fore 
inadvertently exposed to active substances released into the 
environment [10,35]. A comprehensive manner to evaluate the toxicity 
effects on non-target organisms must include the devel- opment of 
specific tests embracing either acute effects (where mortality rates 
are often registered) or chronic effects (by means of exposure to 
different concentrations of a chemical compound over a prolonged 
period of time). In the latter, effects are measured 
  
 
Fig. 4. (a) Acute vs. chronic ecotoxicological studies. (b) Principal endpoints used in ecotoxicological studies, expressed in relative percentage (data collected from 94 articles published between 
1996 and  2009). 
 
through specific parameters such as growth index or reproduc- tion 
rates [52]. Unfortunately, studies on acute effects in organisms belonging 
to different trophic levels (i.e. algae, zooplankton and other 
invertebrates and fish) predominate relatively to chronic ones (Fig. 4). 
Acute toxicity data is only valuable when accidental discharge of the 
drugs occurs, since the environmental concen- trations usually reported 
for these compounds are low, typically in a factor of one thousand. 
Bioaccumulation and chronic toxicity tests are scarce [10,35] probably 
due to the complex experimental work involved. However, recent 
development of sensitive meth- ods for identification and quantification 
of drugs enabled to devise their distribution patterns in several 
environmental samples, thus highlighting the more relevant therapeutic 
classes in terms of envi- ronmental contamination (Fig. 5). These data is 
useful to set out the most appropriate active substances to be used in 
ecotoxicity tests. According to data present in literature, scientific 
community has mainly concerned their attention on therapeutic classes 
such as, non-steroidal anti-inflammatory drugs, blood lipid lowering 
agents, antibiotics and sex hormones. By those reasons, this review will 
focus in the drugs belonging to those therapeutic classes. 
Within this context, some of the acute and chronic toxicity 
effects caused by drugs belonging to different therapeutic classes and 
mixtures of them in non-targets organisms deserve further analysis and 
are discussed in the following section. For a critical analysis of the 
ecotoxicological data present in the literature rel- atively to different 
drugs, we decide to group them according to their main 
pharmacological activity. Therefore, toxicity data will be related to the 
environmental concentrations found by several authors, to establish the 
severity of the situation. 
4.1. Non-steroidal anti-inflammatory drugs 
 
Non-steroidal anti-inflammatory drugs are weak acids acting by 
reversible or irreversible inhibition of one or both isoforms of the 
cyclooxygenase enzymes, COX-1 and COX-2, involved in the 
synthesis of different prostaglandins from arachidonic acid [62]. A 
cyclooxygenase enzyme similar to human COX-2 has been found in fish 
thereby making them a potential target for aquatic contamina- tion [63]. 
Prostaglandins also play an important role in the synthesis of bird eggshells 
and from inhibiting its synthesis, shell thinning has been observed [64]. 
Among the NSAID, diclofenac showed the most acute toxic nature with 
effects being observed at concentrations below 100 mg L−1 [65]. 
Chronic toxicity trials performed on rain- bow trout (Oncorhynchus 
mykiss) evidenced cytological  changes in the liver, kidneys and gills 
after 28 days of exposure to just 1 µg L−1 of diclofenac. For a 
concentration of 5 µg L−1 renal lesions were evident as well as drug 
bioaccumulation in the liver, kid- neys, gills and muscle [66,67]. 
Brown trout (Salmo trutta f. fario) showed similar cytological damage 
and a reduction of haematocrit values after 21 days of exposure to 0.5 µg 
L−1 of this active sub- stance [68]. Schmitt-Jansen et al. [69] evaluated 
both diclofenac phytotoxicity and its photochemical products on the 
unicellular chlorophyte Scenedesmus vacuolatus. Inhibition of algal 
reproduc- tion by the parent compound only occurred at a 
concentration of 23 mg L−1, hence indicating no specific toxicity. 
However, the threat significantly increased when metabolites were 
produced from 53 h of exposure to daylight. Diclofenac also inhibited 
the growth of marine phytoplankton Dunaliella tertiolecta for concen- 
trations of 25 mg L−1 and above [70]. For this organism, 96 h EC50 of 
 
 
 
Fig. 5.  Therapeutic classes detected in the environment, expressed in relative percentage. Data collected from 134 articles published between 1997 and 2009. 
  
 
Table 1 
Examples of concentrations (ng L−1 ) of non-steroidal anti-inflammatory drugs measured in different aquatic environments. 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
Acetylsalicylic acid 50-78-2 Somes river 
water 
Romania SPE-GC–MS 30 (LOQ) <30–37.2 (±4.6) [20] Algae D. subspicatus EC50 (growth 
inhibition) 
106.7 mg L−1 [95] 
Acetylsalicylic acid  STP influent Japan SPE-GC–MS 10 (LOQ) 470–19,400 [86] Crustacean D. magna EC50  (48 h) 88.1 mg L
−1
 [95] 
          (immobilization)   
  STP effluent    38.0–111       
Salicylic acid 69-72-7 STP effluent Canada SPE-GC–MS/MS 0.1 554.3–2178.2 [17] Bacteria V. fischeri EC50  (30 min) 90 mg L
−1
 [83] 
  River water    130.4–371.5       
  Lake water    286.7       
Salicylic acid  STP influent Canada SPE-GC–MS 10 2820–12,700 [18] Algae Scenedesmus EC50  (72 h) >100 mg L
−1
 [83] 
         subspicatus    
  STP effluent    10–320       
        Crustacean D. magna EC50  (24 h) 118 mg L
−1
 [83] 
          (immobilization)   
        Ciliates Tetrahymena EC50 (48 h) (growth >100 mg L
−1
 [83] 
         pyriformis inhibition)   
        Fish B. rerio (zebra LC50 (48 h) 37 mg L
−1
 [83] 
         fish)    
Diclofenac 15307-79-6 STP influent Spain SPE-GC–MS 100 200–3600 [14] Crustacean D. magna EC50  (48 h) 68 mg L
−1
 [65] 
          (immobilization)   
  STP effluent    140–2200       
Diclofenac  STP influent Switzerland SPE-GC–MS 6 1300–2900 [15] Algae D. subspicatus EC50  (growth 72 mg L
−1
 [65] 
          inhibition)   
  STP effluent    1300–2400       
Diclofenac  STP effluent Canada SPE-GC–MS/MS 1.0 32–448 [17] Duckweed L. minor EC50 (7 d) (growth 7.5 mg L
−1
 [65] 
          inhibition)   
Diclofenac  STP influent Canada SPE-GC–MS 10 50–2450 [18] Fish Oncorhynchus LOEC (28 days) 5 µg L
−1
 [66] 
         mykiss (histopathological   
          alterations)   
  STP effluent    70–250       
Diclofenac  STP influent Greece SPE-GC–MS 1 12–560 [19] Fish Oncorhynchus LOEC (28 days) 1 µg L
−1
 [67] 
         mykiss (cytological   
          alterations)   
  STP effluent    10–365       
Diclofenac  STP influent Sweden SPE-GC–MS —† 160 [21] Fish Salmo trout f. 
fario 
NOEC (21 days) 
(histopathological 
0.5 µg L−1 [68] 
          alterations)   
  STP effluent    120       
  Höje river    10–120       
  water           
Diclofenac  Paraíba do Brazil SPE-GC–MS 10 20–60 [22] Algae Dunaliella EC50 (96 h) (growth 185,690 µg L
−1
 [87] 
  Sul river       tertiolecta inhibition)   
  water           
  Drinking           
  water           
      <10–50       
Diclofenac  Groundwater Germany SPE-GC–MS 29 590 [26] Algae D. subspicatus EC50  (growth 71.9 mg L
−1
 [95] 
          inhibition)   
        Crustacean D. magna EC50  (48 h) 68.0 mg L
−1
 [95] 
          (immobilization)   
        Bacteria V. fischeri EC50  (30 min) 11,454 µg L
−1
 [96] 
Diclofenac  Drinking USA SPE-LC–MS/MS 0.25 <0.25 [32] Algae P. subcapitata NOEC (96 h) (growth 10,000 µg L
−1
 [96] 
  water        inhibition)   
Diclofenac  Hospital Taiwan SPE- 10 328 [47]   LOEC (96 h) (growth 20,000 µg L
−1
 [96] 
  effluent  HPLC–MS/MS      inhibition)   
  
 
Table 1 (Continued ) 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
  Pharmaceutical    53       
  production           
  facility           
  effluent           
Diclofenac  STP influent United Kingdom SPE- 20 901–1036 [53] Crustacean D. magna EC50  (48 h) 22,430 µg L
−1
 [96] 
    HPLC–MS/MS      (immobilization)   
  STP effluent    261–598       
Diclofenac  STP influent Spain SPE- 7 21–148 [71]  C. dubia EC50  (48 h) 22,704 µg L
−1
 [96] 
    HPLC–MS/MS      (immobilization)   
  STP effluent Belgium   32–1420       
  River water Germany   26–72       
  Drinking Slovenia   <7       
  water           
Diclofenac  Elber river Germany SPE-GC–MS 0.08 (LOQ) 42–67 [72]   NOEC (7 d) 1000 µg L
−1
 [96] 
  water Alster        (reproduction)   
  lake water           
      26       
Diclofenac  Hospital Spain SPE- 30 60–1900 [73]   LOEC (7 d) 2000 µg L
−1
 [96] 
  effluent  HPLC–MS/MS      (reproduction)   
Diclofenac  STP influent Taiwan SPE- HPLC–
MS/MS 
—† 3–347 [87] Fish D. rerio NOEC (10 d) 
(survival) 
4000 µg L−1 [96] 
  STP effluent    4–101       
Diclofenac  Pearl Rivers 
water 
China GC-NCI-MS 1.1 ND–147 (± 5) [88]   LOEC (10 d) (survival) 8000 µg L
−1
 [96] 
Diclofenac  STP influent Luxembourg SPE-LC–MS/MS 0.3 2–43 [89] Fish O. mykiss LOEC (21 d) (liver 1 µg L
−1
 [97] 
          cytopathology)   
  STP effluent    0.3–78       
  Alzette river    0.3–55       
  water           
  Mess river    0.3–19       
  water           
Diclofenac  STP effluent South Korea SPE-LC–MS/MS 1.0 8.8–127 [90]   LOEC (21 d) (kidney 1 µg L
−1
 [97] 
          cytopathology)   
  Surface water    1.1–6.8       
Diclofenac  STP effluent Spain SPE-LC-QqLIT- 4 (LOQ) 890–1440 [91]   LOEC (21 d) (gills 1 µg L
−1
 [97] 
    MS      cytopathology)   
Diclofenac  STP effluent United Kingdom SPE- 20 350–460 [94]      
    HPLC–MS/MS         
  Surface water    <20–91       
Fenoprofen 53746-45-5 STP influent Japan SPE-GC–MS 1 (LOQ) 9.68–80.6 [86]      
  STP effluent    1.59–9.22       
Ibuprofen 15687-27-1 STP influent Spain SPE-GC–MS 23 34,000–168,000 [14] Crustacean D. magna EC50  (48 h) 108 mg L
−1
 [65] 
          (immobilization)   
  STP effluent    240–28,000       
Ibuprofen  STP influent Switzerland SPE-GC–MS 8 1750–4500 [15] Algae D. subspicatus EC50  (growth 315 mg L
−1
 [65] 
          inhibition)   
  STP effluent    100–1200       
Ibuprofen  STP effluent Canada SPE-GC–MS 0.8 2235.2–6718.3 [17] Duckweed L. minor EC50 (7 d) (growth 22 mg L
−1
 [65] 
          inhibition)   
Ibuprofen  STP influent Canada SPE-GC–MS 10 4100–10,210 [18] Crustacean Daphnia magna EC50  (48 h) 10–100 mg L
−1
 [75] 
          (immobilisation)   
  STP effluent    110–2170       
Ibuprofen  Somes river Romania SPE-GC–MS 30 (LOQ) <30–115.2 [20]   EC50  (14 d) 13.4 mg L
−1
 [75] 
  water        (reproduction)   
  
 
 
 
 
Ibuprofen 
 
STP influent 
 
Sweden 
 
SPE-GC–MS 
 
—† 
(±20.7) 
3590 
 
[21] 
   
NOEC (14 d) 
 
20 mg L−1 
 
[75] 
         (survival)   
 STP effluent    150    LOEC (14 d) (survival)   
 Höje river    10–220     80 mg L
−1
  
 water           
Ibuprofen Paraíba do Brazil SPE-GC–MS 10 <10 [22]   LOEC (14 d) 20 mg L
−1
 [75] 
 Sul river        (population growth)   
 water           
 Drinking           
 water           
     <10       
Ibuprofen Po river Italy SPE- 4.2 (LOQ) ND–9.76 [24] Crustacean Gammarus LOEC (behaviour) 10 ng L−1 [76] 
 water  HPLC–MS/MS     pulex    
 Lambro river    78.50       
 water           
Ibuprofen Groundwater USA SPE-LC–MS 18 3110 [28] Duckweed Lemna minor EC50 (7 d) (growth 4.01 mg L
−1
 [77] 
         inhibition)   
Ibuprofen Hospital Taiwan SPE- 25 119 [47] Crustacean T. platyurus LC50 (24 h) 19.59 mg L
−1
 [78] 
 effluent  HPLC–MS/MS      (mortality)   
 Pharmaceutical    45,875       
 production           
 facility           
 effluent           
Ibuprofen STP influent United Kingdom SPE- 20 7741–33,764 [53] Fish O. latipes LC50 (96 h) >100 mg L
−1
 [79] 
   HPLC–MS/MS      (mortality)   
 STP effluent    1979–4239       
 Tyne river    144–2370       
 water           
Ibuprofen STP influent Spain SPE- 12 37–860 [71] Mollusc P. carinatus LC50 (72 h) (survival) 17.1 mg L
−1
 [79] 
   HPLC–MS/MS         
 STP effluent Belgium   18–1860       
 River water Germany   60–152       
 Drinking Slovenia   <12       
 water           
Ibuprofen Elber river Germany SPE-GC–MS 0.05 (LOQ) 8.7–32 [72]   NOEC (21 d) 5.36 mg L
−1
 [79] 
 water        (survival)   
 Alster lake    4.9       
 water           
Ibuprofen Hospital Spain SPE- 31 1500–151,000 [73]   NOEC (21 d) (growth) 1.02 mg L
−1
 [79] 
 effluent  HPLC–MS/MS         
Ibuprofen STP effluent USA SPE-GC–MS 10 18 (±14%) [81]   LOEC (21 d) (growth) 2.43 mg L
−1
 [79] 
Ibuprofen STP influent Japan SPE-GC–MS 1 (LOQ) 407–1130 [86]   NOEC (21 d) 2.43 mg L
−1
 [79] 
         (reproduction)   
 STP effluent    1.41–177       
Ibuprofen STP influent Taiwan SPE- HPLC–
MS/MS 
—† 711–17,933 [87] Algae D. subspicatus EC50 (growth 
inhibition) 
342.2 mg L−1 [95] 
 STP effluent    313–3777       
Ibuprofen STP influent Luxembourg SPE-LC–MS/MS 0.3 82–3080 [89] Crustacean D. magna EC50  (48 h) 101.2 mg L
−1
 [95] 
         (immobilization)   
 STP effluent    3–359       
 Alzette river    10–295       
 water           
 Mess river    9–2383       
 water           
Ibuprofen STP effluent South Korea SPE-LC–MS/MS 1.0 10–137 [90] Cnidarian Hydra LC50 (96 h) 22.36 mg L
−1
 [98] 
        attenuata (morphology)   
 Surface water    11–38       
  
 
Table 1 (Continued ) 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
  Drinking    <1.0       
  water           
Ibuprofen  STP effluent Spain SPE-LC-QqLIT- 13 (LOQ) 100–340 [91]   EC50  (96 h) 1.65 mg L
−1
 [98] 
    MS      (morphology)   
Ibuprofen  Mankyung 
river water 
South Korea SPE-LC–MS/MS 5 <5–414 (±13) [92]   LOEC (96 h) 
(morphology) 
1 mg L−1 [98] 
Ibuprofen  STP effluent United Kingdom SPE- 20 1700–3800 [94]   NOEC (96 h) 0.1 mg L
−1
 [98] 
    HPLC–MS/MS      (morphology)   
  Surface water    <20       
          EC50 (96 h) (feeding) 3.85 mg L
−1
 [98] 
Carboxy-ibuprofen* —† STP influent Sweden SPE-GC–MS —† 10,750 [21]      
  STP effluent    430       
  Höje river    230–680       
  water           
Carboxy-ibuprofen*  Elber river Germany SPE-GC–MS 0.21 11–32 [72]      
  water           
  Alster lake    9.5       
  water           
Hydroxy-ibuprofen* —† STP influent Sweden SPE-GC–MS —† 990 [21]      
  STP effluent    50       
  Höje river    20–60       
  water           
Hydroxy-ibuprofen*  Elber river Germany SPE-GC–MS 0.38 32–101 [72]      
  water           
  Alster lake    18       
  water           
Indomethacin 53-86-1 STP influent Canada SPE-GC–MS 10 30–430 [18]      
  STP effluent    40–490       
Indomethacin  STP effluent Spain SPE-LC-QqLIT- 8 (LOQ) 160–390 [91] Crustacean T. platyurus LC50 (24 h) 16.14 mg L
−1
 [78] 
    MS      (mortality)   
Indomethacin  Mankyung 
river water 
South Korea SPE-LC–MS/MS 1 <1–33.5 (±8) [92] Fish O. latipes LC50 (96 h) 
(mortality) 
81.92 mg L−1 [78] 
Ketoprofen 22071-15-4 STP effluent Canada SPE-GC–MS/MS 1.0 8–351 [17]  
Ketoprofen  STP influent Canada SPE-GC–MS 10 60–150 [18] 
  STP effluent    40–90  
Ketoprofen  STP influent Sweden SPE-GC–MS —† 940 [21] 
  STP effluent    330  
  Höje river    10–70  
  water      
Ketoprofen  Hospital Taiwan SPE- 10 9.6 [47] 
  effluent  HPLC–MS/MS    
  Pharmaceutical    ND  
  production      
  facility      
  effluent      
Ketoprofen  STP influent Spain SPE- 26 131 [71] 
    HPLC–MS/MS    
  STP effluent Belgium   <26  
  River water Germany   <26  
  Drinking Slovenia   <26  
  water      
Ketoprofen  STP effluent USA SPE-GC–MS 9 23 (±6.8%) [81] 
Ketoprofen  STP influent Japan SPE-GC–MS 0.3 (LOQ) 108–369 [86] 
  STP effluent    68.1–219  
  
 
 
Ketorolac 74103-06-3 Hospital 
effluent 
Spain SPE- HPLC–
MS/MS 
26 200–59,500 [73]  
Mefenamic acid 61-68-7 STP influent United Kingdom SPE- 50 136–363 [53] Crustacean T. platyurus LC50 (24 h) 3.95 mg L
−1
 [78] 
    HPLC–MS/MS      (mortality)   
  STP effluent    290–396       
Mefenamic acid  STP effluent Japan SPE-GC–MS 1 (LOQ) 4.45–396 [86] Fish O. latipes LC50 (96 h) 8.04 mg L
−1
 [78] 
          (mortality)   
Mefenamic acid  Pearl Rivers 
water 
China GC-NCI-MS 2.2 ND–22.4 (±3.1) [88]      
Mefenamic acid  STP effluent Spain SPE-LC-QqLIT- 3 (LOQ) 40–60 [91]      
    MS         
Mefenamic acid  Mankyung 
river water 
South Korea SPE-LC–MS/MS 10 <10–326 (±21) [92]      
Mefenamic acid  STP effluent United Kingdom SPE- 50 720–1100 [94]      
    HPLC–MS/MS         
  Surface water    <50–65       
Naproxen 22204-53-1 STP effluent Canada SPE-GC–MS/MS 0.5 271.4–7962.3 [17] Crustacean D. magna EC50  (48 h) 174 mg L
−1
 [65] 
          (immobilization)   
Naproxen  STP influent Canada SPE-GC–MS 10 1730–6030 [18] Algae D. subspicatus EC50  (growth >320 mg L
−1
 [65] 
          inhibition)   
  STP effluent    360–2540       
Naproxen  STP influent Sweden SPE-GC–MS —† 3650 [21] Duckweed L. minor EC50 (7 d) (growth 
inhibition) 
24.2 mg L−1 [65] 
  STP effluent    250       
  Höje river    90–250       
  water           
Naproxen  Paraíba do Brazil SPE-GC–MS 10 <10–50 [22] Rotifers B. calyciflorus LC50 (24 h) 62.48 mg L
−1
 [80] 
  Sul river           
  water           
  Drinking           
  water           
      <10–30       
Naproxen  Drinking USA SPE-LC–MS/MS 0.5 <0.5 [32] Rotifers T. platyurus LC50 (24 h) 84.09 mg L
−1
 [80] 
  water           
Naproxen  Hospital Taiwan SPE- 10 698 [47] Crustaceans C. dubia EC50  (24 h) 66.37 mg L
−1
 [80] 
  effluent  HPLC–MS/MS      (immobilization)   
  Pharmaceutical    ND       
  production           
  facility           
  effluent           
Naproxen  STP influent Spain SPE- 26 109–455 [71] Algae P. subcapitata EC50 (72 h) (growth 31.82 mg L
−1
 [80] 
    HPLC–MS/MS      inhibition)   
  STP effluent Belgium   625       
  River water Germany   70       
  Drinking Slovenia   <26       
  water           
Naproxen  STP effluent USA SPE-GC–MS 9 31 (±5.5%) [81] Rotifers B. calyciflorus EC50 (48 h) (growth 
inhibition) 
0.56 mg L−1 [80] 
Naproxen  STP influent Japan SPE-GC–MS 0.3 (LOQ) 38.0–230 [86] Crustaceans C. dubia EC50 (7 d) (population 0.33 mg L
−1
 [80] 
          growth inhibition)   
  STP effluent    12.0–139       
Naproxen  Pearl Rivers 
water 
China GC-NCI-MS 1.3 ND–118 (±10.1) [88] Algae D. subspicatus EC50 (growth 
inhibition) 
625.5 mg L−1 [95] 
Naproxen  STP effluent South Korea SPE-LC–MS/MS 1.0 20–483 [90] Crustacean D. magna EC50  (48 h) 166.3 mg L
−1
 [95] 
          (immobilization)   
  Surface water    1.8–18       
        Cnidarian Hydra LC50 (96 h) 22.36 mg L
−1
 [98] 
         attenuata (morphology)   
          EC50  (96 h) 2.62 mg L
−1
 [98] 
          (morphology)   
  
 
 
 
 
 
 
Table 1 (Continued ) 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
          LOEC (96 h) 5 mg L−1 [98] 
          (morphology)   
          NOEC (96 h) 1 mg L
−1
 [98] 
          (morphology)   
          EC50 (96 h) (feeding) 2.68 mg L
−1
 [98] 
Paracetamol 103-90-2 STP influent Spain SPE-GC–MS 32 29,000–246,000 [14] Bacteria V. fischeri EC50  (15 min) 567.5 mg L
−1
 [82] 
  STP effluent    <32–4300       
Paracetamol  Groundwater USA SPE-LC–MS 9 380 [28] Crustacean D. magna EC50  (48 h) 30.1 mg L
−1
 [82] 
          (immobilization)   
Paracetamol  Hospital Taiwan SPE- 2 62,250 [47]  D. magna EC50  (96 h) 26.6 mg L
−1
 [82] 
  effluent  HPLC–MS/MS      (immobilization)   
  Pharmaceutical    124       
  production           
  facility           
  effluent           
Paracetamol  STP influent United Kingdom SPE- 20 5529–69,570 [53] Fish O. latipes LC50 (48 h) >160 mg L
−1
 [82] 
    HPLC–MS/MS         
  STP effluent    <20       
Paracetamol  Hospital Spain SPE- 47 500–29,000 [73]  O. latipes LC50 (96 h) >160 mg L
−1
 [82] 
  effluent  HPLC–MS/MS         
Paracetamol  Danube river Serbia SPE-LC–MS/MS 0.50 78,170 [84] Bacteria V. fischeri EC50  (30 min) 650 mg L
−1
 [83] 
  water           
  Sava river    610       
  water           
  Tamisˇ  river    310       
  water           
Paracetamol  STP effluent South Korea SPE-LC–MS/MS 1.0 1.8–19 [90] Algae Scenedesmus EC50  (72 h) 134 mg L
−1
 [83] 
         subspicatus    
  Surface water    4.1–73       
Paracetamol  STP influent Korea SPE-LC–MS 5 13,046–56,944 [93] Crustacean D. magna EC50 (immobilization) 50 mg L
−1
 [83] 
  STP effluent    <5–9       
  Han river    <5–127       
  water           
Paracetamol  STP effluent United Kingdom SPE- 50 <50 [94] Ciliates Tetrahymena EC50 (48 h) (growth 112 mg L
−1
 [83] 
    HPLC–MS/MS     pyriformis inhibition)   
  Surface water    <50       
        Fish B. rerio (zebra LC50 (48 h) 378 mg L
−1
 [83] 
         fish)    
*—Metabolite; †—Data not available; ND—Not detected; SPE—Solid Phase Extraction; GC–MS—Gas Chromatography with Mass Spectrometry Detection; GC–MS/MS—Gas Chromatography with Tandem Mass Spectrometry Detection; GC-
NCI-MS—Gas Chromatography-Negative Chemical Ionization-Mass Spectrometry; HPLC–MS/MS—High Performance Liquid Chromatography with Tandem Mass Spectrometry Detection; LC-QqLIT-MS—Liquid chromatography-quadrupole-linear 
ion trap-mass spectrometry detection. 
 185.69 mg L−1 was found [70]. Diclofenac was detected in STP efflu- ents 
at maximum concentrations of 2.4 [15] and 1.42 µg L−1 [71] in 
Switzerland and Belgium respectively (Table 1) which highlighted that 
the effects cited are of sufficient magnitude to suspect chronic toxicity in 
aquatic organisms. Diclofenac has also been found in rivers 
[21,22,72], groundwater [26], hospital effluents [47,73] and drinking 
water [22,32,71] but at concentrations in the order of ng L−1. 
Ibuprofen is another NSAID with documented chronic toxic- ity. 
Female Japanese medaka (the Japanese killifish, Oryzias latipes) 
exposed to different concentrations of the drug over six weeks, showed 
a sharp rise in liver weight together with enhanced egg production, yet 
with a reduction in the number of weekly spawning events [74]. Authors 
associated these phenomena with changes in the spawning process and 
vitellogenin production, a glycoprotein precursor in yolk formation. 
With the water flea Daphnia magna population growth rate was 
significantly reduced for concentra- tions ranging from 0 to 80 mg L−1 
[75]. Reproduction was affected at all concentrations and completely 
inhibited at the highest phar- maceutical levels. An activity decrease of 
the freshwater amphipod Gammarus pulex was noticed when in contact 
with ibuprofen con- centrations of 1 and 10 ng L−1, the latter value 
corresponding to the LOEC3 obtained for behaviour change [76]. 
Regarding aquatic pho- tosynthetic organisms, specific effects have 
been noticed. A 5-day exposure to concentrations in the 1–1000 µg L−1 
range stimulated the growth of the cyanobacterium Synechocystis sp. 
while inhibiting that of the duckweed plant Lemna minor after 7 days 
[77]. Ibupro- fen has been detected in STP effluents at concentrations 
that can reach 28 µg L−1 [14] (Spain) (Table 1). Two metabolites of 
ibuprofen (carboxyl-ibuprofen and hydroxyl-ibuprofen) were also 
found in surface waters and in a Swedish STP (influent and effluent) 
[21,72]. Due to demonstrable chronic toxicity, this may represent a 
real threat to non-target organisms, even at those lower concentra- 
tions. Ibuprofen was also found in rivers [20–22,24,72] and drinking water 
[22] which may broaden the scope of the problem to public health. 
However, effects in humans caused by chronic exposure to this active 
substance still remain unknown. 
The ecotoxicity of naproxen and its photoderivative products have 
also been envisaged. Acute toxicity tests performed on the rotifer 
Brachionus calyciflorus, the water flea Ceriodaphnia dubia and the fairy 
shrimp Thamnocephalus platyurus, showed that naproxen had LC50
4 
and EC50
5 values within the 1–100 mg L−1 range, with the photolysis 
products being significantly more toxic [80]. Highly chronic toxic 
properties were equally noticed with algae being the less sensitive 
organisms. Yet again, degradation products were shown to be more 
toxic with EC50  values of 26 and 62 µg L
−1  for 
C. dubia, relative to growth inhibition. Naproxen had been found in STP 
effluents in a concentration range between 31 ng L−1 [81] and 
7.96 µg L−1 [17] and in surface waters [21,22,71], at concentration 
levels that can reach 250 ng L−1 [21]. This active substance was also 
detected in drinking water [22,32,71]. 
The highly prescribed paracetamol (or acetaminophen) is a weak 
inhibitor of the cyclooxygenase enzyme, whose side effects are mainly 
associated with the formation of hepatotoxic metabo- lites, such as N-
acetyl-p-benzoquinone imine (NAPQI) when the levels of liver 
glutathione are low [36]. Tests were carried out on algae, water fleas, 
fish embryos, luminescent bacteria and ciliates. The most sensitive 
species was shown to be D. magna for which EC50 values of 30.1 [82] or 
50 mg L−1 [83] were reported. Some authors reported the presence of 
paracetamol in STP effluents at concen- trations below to 20 ng L−1  
[53] to 4.3 µg L−1  [14], and in surface 
 
 
 
3   LOEC—Lowest Observed Effect Concentration. 
4 LC50 —Half Maximal Lethal Concentration. 
5 EC50 —Half Maximal Effective Concentration. 
 
waters, values can reach 78.17 µg L−1 [84] (Table 1), which are val- ues 
higher than the predicted no-effect concentration (PNEC)  of 
9.2 µg L−1  [85]. Hence, paracetamol might represent a threat  for 
non-target organisms. 
 
 
4.2. Blood lipid lowering agents 
 
Modulating drugs for lipid metabolism are frequently pre- 
scribed in the developed world and aim to decrease the concentration 
of blood circulating cholesterol and triglycerides. Pharmaceuticals 
belonging to this therapeutic class can be divided into two main 
groups: statins and the group most frequently detected in the 
environment, fibrates [99]. Statins act by inhibiting the 3-
hydroxymethylglutaryl coenzyme A reductase (HMG-CoA), an enzyme 
involved in feedback control of cholesterol synthesis. In response, the 
number of LDL lipoprotein receptors at hepatocyte surfaces increases, 
thus lowering the circulating LDL cholesterol [100]. Toxicity data of 
statins on different organisms is very limited and restricted to the active 
substances simvastatin and atorvas- tatin. After an exposure of 96 h to 
simvastatin, larval and adult grass shrimp (Palaemonetes pugio) 
showed a LC50 of 1.18 mg L
−1 and upper 10 mg L−1, respectively 
[101], while the harpacticoid copepod Nitocra spinipes had a 96-h 
LC50 of 0.81 mg L
−1 [102]. Dahl et al. (2006) [102] also reported a 
significantly increase in development time and body length of the 
copepod for a range of concentrations between 0.16 and 1.6 µg L−1. On 
the other hand, simvastatin exhibited an EC50 of 22.8 mg L
−1, after 96 
h, for the marine phytoplankton D. tertiolecta [70]. Relatively to 
atorvastatin, this active substance can affect the development of the 
duckweed Lemna gibba, showing a LOEC of 300 µg L−1 for 
parameters such as wet mass, frond number, chlorophyll-a and 
carotenoids con- tent, for a time of exposure of 7 days [103]. Apart 
from statins had also the ability to suppress synthesis of the juvenile 
hormone in insects [104]. Statins were found in untreated sewage 
sam- ples (Table 2) at concentrations between 4 and 117 ng L−1 and in 
treated sewage samples at 1–59 ng L−1 [105,106]. Additionally, they were 
also detected in surface water [105] and drinking water [32] at 
concentrations that can reach 1 ng L−1. In turn, fibrates act by 
activating specific transcription factors belonging to the nuclear 
hormone receptor super family, known as peroxisome proliferator- 
activated receptors (PPARs) [107]. There are three types of PPARs 
related to different cellular events. PPAR-a and PPAR-� play key roles 
in catabolism and storage of fatty acids while PPAR-)' plays an 
important role in cellular differentiation [108]. Some authors have 
reported a proliferation of peroxisomes in rodent livers caused by fibrates 
[10]. Embryonic development of non-target organisms that share these 
receptors can be stopped by simply inhibiting cellular differentiation. 
Fibrates present in the micromolar con- centration range are sufficient 
to cause it in zebrafish (Danio rerio) [109,110] and amphibians [111]. 
Raldúa et al. [110] demonstrated that, when exposed to 0.5–1 mg L−1 
of clofibrate, zebrafish larvae had a significantly shorter body length and 
their morphologic char- acteristics were also altered. Clofibrate-exposed 
zebrafish larvae had also lethargic behaviour. It was evidenced that 
gemfibrozil and bezafibrate significantly affect feeding, attachment and 
hydrant growth of the cnidarian Hydra attenuata [98]. According to 
Quinn et al. [98], gemfibrozil could be classified as toxic (EC50 between 
1 and 10 mg L−1) and bezafibrate as harmful for non-target organisms 
(EC50 between 10 and 100 mg L
−1). Toxic properties of gemfibrozil were 
also respectively investigated on the inhibition of the bac- terium 
Vibrio fischeri luminescence, growth inhibition of the alga Chlorella 
vulgaris and on the immobilization of the D. magna. In this study 
both the bacteria and the water flea were shown to be sensitive to 
gemfibrozil with the latter being the most sensitive, having an EC50 of 
30 mg L−1 after 72 h [112]. Proliferative inhibition 
  
 
Table 2 
Examples of concentrations (ng L−1 ) of blood lipid lowering agents measured in different aquatic environments. 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
Fibrates             
Bezafibrate 41859-67-0 Paraíba do Brazil SPE-GC–MS 25 <25 [22] Cnidarian Hydra LC50 (96 h) 70.71 mg L
−1
 [98] 
  Sul river       attenuata (morphology)   
  water           
  Drinking           
  water           
      <25       
Bezafibrate  Po river Italy SPE- 0.3 0.79–2.75 [24]   EC50  (96 h) 25.85 mg L
−1
 [98] 
  water  HPLC–MS/MS      (morphology)   
  Lambro river    57.15       
  water           
Bezafibrate  STP effluent Spain SPE-LC-QqLIT- 3 (LOQ) 40–130 [91]   LOEC (96 h) 1 mg L
−1
 [98] 
    MS      (morphology)   
Bezafibrate  STP effluent Italy SPE- 0.1 (LOQ) 0.3–117 [118]   NOEC (96 h) 0.1 mg L
−1
 [98] 
    HPLC–MS/MS      (morphology)   
          EC50 (96 h) (feeding) 8.59 mg L
−1
 [98] 
        Rotifer B. calyciflorus LC50 (24 h) 60.91 mg L
−1
 [113] 
          (mortality)   
          EC50  (48 h) 0.44 mg L
−1
 [113] 
          (population growth   
          inhibition)   
          NOEC (48 h) 0.156 mg L
−1
 [113] 
          LOEC (48 h) 0.3125 mg L
−1
 [113] 
        Crustacean T. platyurus LC50 (24 h) 39.69 mg L
−1
 [113] 
          (mortality)   
         D. magna EC50  (24 h) 100.08 mg L
−1
 [113] 
          (immobilization)   
         C. dubia EC50  (48 h) 75.79 mg L
−1
 [113] 
          (immobilization)   
          EC50 (7 d) (population 0.13 mg L
−1
 [113] 
          growth inhibition)   
          NOEC (7 d) 0.023 mg L
−1
 [113] 
          LOEC (7 d) 0.047 mg L
−1
 [113] 
Clofibrate 82115-62-6       Fish D. rerio LC50 (96 h) 0.89 mg L
−1
 [110] 
          (mortality)   
Fenofibrate 49562-28-9       Rotifer B. calyciflorus LC50 (24 h) 64.97 mg L
−1
 [113] 
          (mortality)   
          EC50  (48 h) 1.44 mg L
−1
 [113] 
          (population growth   
          inhibition)   
          NOEC (48 h) 0.156 mg L
−1
 [113] 
          LOEC (48 h) 0.3125 mg L
−1
 [113] 
        Crustacean D. magna EC50  (24 h) 50.12 mg L
−1
 [113] 
          (immobilization)   
         C. dubia EC50 (7 d) (population 0.76 mg L
−1
 [113] 
          growth inhibition)   
          NOEC (7 d) 0.039 mg L
−1
 [113] 
          LOEC (7 d) 0.078 mg L
−1
 [113] 
        Algae P. subcapitata EC50 (72 h) (growth 19.84 mg L
−1
 [113] 
          inhibition)   
          NOEC (72 h) 3.12 mg L
−1
 [113] 
          LOEC (72 h) 6.25 mg L
−1
 [113] 
Clofibric acid* 882-09-7 STP influent Greece SPE-GC–MS 1.8 ND [19] Crustacean D. magna EC50  (48 h) 72 mg L
−1
 [65] 
          (immobilization)   
  
 
 
 
 
Clofibric acid* 
 STP effluent 
Paraíba do 
 
Brazil 
 
SPE-GC–MS 
 
10 
5 
<10–30 
 
[22] 
 
Algae 
 
D. subspicatus 
 
EC50  (growth 
 
115 mg L−1 
 
[65] 
  Sul river        inhibition)   
  water           
  Drinking           
  water           
      <10–20       
Clofibric acid*  Po river Italy SPE- 0.3 0.41–5.77 [24] Duckweed L. minor EC50 (7 d) (growth 12.5 mg L
−1
 [65] 
  water  HPLC–MS/MS      inhibition)   
  Lambro river    ND       
  water           
Clofibric acid*  North Sea 
water 
—† SPE-GC–MS 0.008 ND–18.6 [25] Bacteria V. fischeri EC50  (30 min) 100 mg L
−1
 [83] 
Clofibric acid*  STP influent United Kingdom SPE- 20 <20–651 [53] Algae Scenedesmus EC50  (72 h) 89 mg L
−1
 [83] 
    HPLC–MS/MS     subspicatus    
  STP effluent    <20–44       
Clofibric acid*  STP influent Spain SPE- 17 25–58 [71] Crustacean D. magna EC50 (immobilization) 106 mg L
−1
 [83] 
    HPLC–MS/MS         
  STP effluent Belgium   22–107       
  River water Germany   24–35       
  Drinking Slovenia   <17       
  water           
Clofibric acid*  Elbe river Germany SPE-GC–MS 0.26 (LOQ) 3.2–7.6 [72] Ciliates Tetrahymena EC50 (48 h) (growth 175 mg L
−1
 [83] 
  water       pyriformis inhibition)   
  Alster lake    2.4       
  water           
Clofibric acid*  STP influent Taiwan SPE- HPLC–
MS/MS 
—† 36–2593 [87] Fish D. rerio LC50 (48 h) 86 mg L
−1
 [83] 
  STP effluent    47–487       
Clofibric acid*  STP effluent Spain SPE-LC-QqLIT- 4 (LOQ) 36–51 [91] Algae Dunaliella EC50 (96 h) (growth 224,180 µg L
−1
 [87] 
    MS     tertiolecta inhibition)   
Clofibric acid*  STP effluent United Kingdom SPE- 50 <50 [94] Bacteria V. fischeri EC50  (30 min) 91,827 µg L
−1
 [96] 
    HPLC–MS/MS         
  Surface water    <50       
Clofibric acid*  STP effluent Italy SPE- 0.36 (LOQ) ND–82 [118] Algae P. subcapitata NOEC (96 h) (growth 75,000 µg L
−1
 [96] 
    HPLC–MS/MS      inhibition)   
Clofibric acid*  Groundwater Germany SPE-GC–MS 2 (LOQ) 2–40 [119]   LOEC (96 h) (growth 150,000 µg L
−1
 [96] 
          inhibition)   
        Crustacean D. magna EC50  (48 h) >200,000 µg L
−1
 [96] 
          (immobilization)   
         C. dubia EC50  (48 h) >200,000 µg L
−1
 [96] 
          (immobilization)   
          NOEC (7 d) 640 µg L
−1
 [96] 
          (reproduction)   
          LOEC (7 d) 2560 µg L
−1
 [96] 
          (reproduction)   
        Fish D. rerio NOEC (10 d) 70,000 µg L
−1
 [96] 
          (survival)   
          LOEC (10 d) (survival) 140,000 µg L
−1
 [96] 
        Fish O. mykiss LOEC (21 d) (liver >100 µg L
−1
 [97] 
          cytopathology)   
          LOEC (21 d) (kidney >100 µg L
−1
 [97] 
          cytopathology)   
          LOEC (21 d) (gills 5 µg L
−1
 [97] 
          cytopathology)   
Gemfibrozil 25812-30-0 STP effluent Canada SPE-GC–MS/MS 0.3 80.1–478.2 [17] Cnidarian Hydra LC50 (96 h) 22.36 mg L
−1
 [98] 
         attenuata (morphology)   
  River water    ND–18.4       
  Lake water    ND       
  
 
Table 2 (Continued ) 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
Gemfibrozil  STP influent Canada SPE-GC–MS 10 120–36,530 [18]   EC50  (96 h) 1.18 mg L−1 [98] 
          (morphology)   
  STP effluent    80–2090       
Gemfibrozil  STP influent Sweden SPE-GC–MS —† 710 [21]   LOEC (96 h) 
(morphology) 
1 mg L−1 [98] 
  STP effluent    180       
  Höje river    1–170       
  water           
Gemfibrozil  Drinking USA SPE-LC–MS/MS 0.25 0.43 [32]   NOEC (96 h) 0.1 mg L
−1
 [98] 
  water        (morphology)   
Gemfibrozil  Hospital Taiwan SPE- 1.0 760 [47]   EC50 (96 h) (feeding) 1.76 mg L
−1
 [98] 
  effluent  HPLC–MS/MS         
  Pharmaceutical    1795       
  production           
  facility           
  effluent           
Gemfibrozil  Pearl rivers 
water 
China SPE-GC-NCI-MS 1.8 ND–22.4 (±3.1) [88] Bacteria V. fischeri EC50  (24 h) 
(bioluminescence) 
64.6 mg L−1 [112] 
Gemfibrozil  STP effluent South Korea SPE-LC–MS/MS 1.0 3.9–17 [90]   EC50  (48 h) 45.1 mg L
−1
 [112] 
          (bioluminescence)   
  Surface water    1.8–9.1       
Gemfibrozil  STP effluent Spain SPE-LC-QqLIT- 4 (LOQ) 470–3550 [91] Algae Chlorella EC50  (24 h) (growth) 195 mg L
−1
 [112] 
    MS     vulgaris    
          EC50  (48 h) (growth) 161 mg L
−1
 [112] 
          EC50  (72 h) (growth) 150 mg L
−1
 [112] 
        Crustacean D. magna EC50  (24 h) 57.1 mg L
−1
 [112] 
          (immobilization)   
          EC50  (48 h) 42.6 mg L
−1
 [112] 
          (immobilization)   
          EC50  (72 h) 30.0 mg L
−1
 [112] 
          (immobilization)   
        Bacteria V. fischeri EC50  (30 min) 85.74 mg L
−1
 [113] 
          (bioluminescence)   
        Rotifer B. calyciflorus LC50 (24 h) 77.30 mg L
−1
 [113] 
          (mortality)   
          EC50  (48 h) 0.44 mg L
−1
 [113] 
          (population growth   
          inhibition)   
          NOEC (48 h) 0.156 mg L
−1
 [113] 
          LOEC (48 h) 0.312 mg L
−1
 [113] 
        Crustacean T. platyurus LC50 (24 h) 161.05 mg L
−1
 [113] 
          (mortality)   
         D. magna EC50  (24 h) 74.30 mg L
−1
 [113] 
          (immobilization)   
         C. dubia EC50 (7 d) (population 0.53 mg L
−1
 [113] 
          growth inhibition)   
          NOEC (7 d) 0.078 mg L
−1
 [113] 
          LOEC (7 d) 0.156 mg L
−1
 [113] 
        Algae P. subcapitata EC50 (72 h) (growth 15.19 mg L
−1
 [113] 
          inhibition)   
          NOEC (72 h) 3.125 mg L
−1
 [113] 
          LOEC (72 h) 6.25 mg L
−1
 [113] 
Statins             
Atorvastatin 134523-03-8 Drinking USA SPE-LC–MS/MS 0.25 <0.25 [32] Duckweed L. gibba LOEC (7 d) (growth 300 µg L−1 [103] 
  water        parameters)   
  
 
 
 
 
 
 
 
 
Atorvastatin  STP influent 
STP effluent 
Otonabee 
Canada SPE-LC–MS/MS 0.1 76 (±3) 
37 (±2) 
[105]  
  river water      
 
Atorvastatin 
  
STP effluent 
 
Canada 
 
SPE-LC–MS/MS 
 
0.001 
1 (±0) 
22.4 (±1.4) 
 
[106] 
o-hydroxy atorvastatin* 214217-86-6 Drinking USA SPE-LC–MS/MS 0.50 <0.50 [32] 
  water      
p-hydroxy atorvastatin* 214217-88-6 Drinking USA SPE-LC–MS/MS 0.50 <0.50 [32] 
  water      
Lovastatin 81739-26-6 STP influent 
STP effluent 
Otonabee 
Canada SPE-LC–MS/MS 0.1 49 (±2) 
14 (±1) 
[105] 
  river water      
      ND  
Pravastatin 81131-70-6 STP influent 
STP effluent 
Otonabee 
Canada SPE-LC–MS/MS 1.0 117 (±6) 
59 (±2) 
[105] 
  river water      
      ND  
Simvastatin 79902-63-9 STP influent Canada SPE-LC–MS/MS 0.1 4 (±0) [105] Algae Dunaliella 
tertiolecta 
EC50 (96 h) (growth 
inhibition) 
22,800 µg L−1 [70] 
  STP effluent 
Otonabee 
   1 (±0)       
  river water           
      ND       
 Grass shrimp Palaemonetes LC50 (96 h) (larvae 1.18 mg L
−1
 [101] 
 pugio survival)   
  NOEC (larvae 0.625 mg L
−1
 [101] 
  survival)   
  LOEC (larvae survival) 1.25 mg L
−1
 [101] 
  LC50 (96 h) (adult >10 mg L
−1
 [101] 
  survival)   
  NOEC (adult survival) 5.00 mg L
−1
 [101] 
  LOEC (adult survival) 10.0 mg L
−1
 [101] 
Copepod Nitocra spinipes LC50 (96 h) (growth 810 µg L
−1
 [102] 
  rate)   
  LOEC (growth rate) 0.16 µg L
−1
 [102] 
*—Metabolite; †—Data not available; ND—Not detected; SPE—Solid Phase Extraction; GC–MS—Gas Chromatography with Mass Spectrometry Detection; GC–MS/MS—Gas Chromatography with Tandem Mass Spectrome- try Detection; GC-
NCI-MS—Gas Chromatography-Negative Chemical Ionization-Mass Spectrometry; HPLC–MS/MS—High Performance Liquid Chromatography with Tandem Mass Spectrometry Detection; LC–MS/MS—Liquid Chromatography with Tandem Mass 
Spectrometry Detection. 
 of C. vulgaris was only observed for concentrations up to 150 mg L−1 
[112]. Isidori et al. [113] studied the acute and chronic toxicities 
caused by bezafibrate, fenofibrate and gemfibrozil and their pho- 
toproducts on non-target organisms, considering that they did not 
significantly affect the exposed organisms (LC50 values ranged from 
39.69 to 161.05 mg L−1). When goldfish (Carassius  auratus)  were 
exposed to 1.5 µg L−1 of gemfibrozil for 14 days, a decrease of more than 
50% in plasma testosterone levels was noticed [114], thereby proving 
that this pharmaceutical may also act as an endocrine dis- ruptor. As the 
main active metabolite of several fibrate compounds, clofibric acid is 
frequently used to assess toxicity due to its high degree of persistence 
in the environment. In acute toxicity tests on bacteria, ciliates, 
daphnids and fish embryos, Ferrari et al. [96] noticed low toxicity when 
at concentrations up to 14 mg L−1. These results are in agreement with 
the tests performed on three estuar- 
ine species: algae D. tertiolecta, crustacean P. pugio and fish Fundulus 
heteroclitus [115]. For concentrations ≤1000 µg L−1, clofibric acid did 
not significantly affect cell density and growth rate of the first, neither 
did it affect the survival of the remainder. This is in agree- 
ment with the 96-h EC50 of 224.18 mg L
−1 found for D. tertiolecta 
[87]. On the contrary, exposure to concentrations above 10 µg L−1 and 
up to 100 µg L−1  increased the proportion of male offspring 
produced by D. magna [116]. Rotifers have also shown to be sen- 
sitive and a NOEC6 value of 250 µg L−1 was deduced [96]. Fathead 
minnow fish (Pimephales promelas) showed alterations in repro- 
ductive function expressed by a reduction in sperm motility and 
plasma androgen concentration [117] while cytological changes in 
gills were noticed in rainbow trout exposed to 5 µg L−1 of this 
metabolite [97]. Fibrates (as bezafibrate and gemfibrozil) have been 
detected in several environmental samples (Table 2). Bezafibrate was 
found in STP effluents [91,118] and in the Paraíba do Sul river 
(Brazil) [22] as was gemfibrozil [17,18,21] and further iden- tified in 
surface waters [17,21,88]. Due to its greater persistence, clofibric acid 
has been found in STP influents [19,71] and effluents [19,53,71], 
surface water [22,24,71], drinking water [71,119] and North Sea water 
[25]. All of these pharmaceuticals were shown to be present at 
concentration levels in the order of ng L−1  or    low 
µg L−1, which indicates that their exposure may represent a threat for 
non-target organisms. 
 
4.3. Antibiotics 
 
Antibiotics come within a therapeutic class where human health 
preservation and environmental disturbance are closely related. The 
major concern is associated with the development of resistance 
mechanisms by bacteria which can subsequently compromise pub- 
dity or sex ratio [116]. Similar results were obtained after chronic 
exposure to 10 µg L−1 of sulfamethoxazole [116]. Amoxicillin con- 
centrations ranging from 50 ng L−1 to 50 mg L−1 were tested on four 
different algae without observable effects, unless for the blue-green algae 
Synechococcus leopolensis for which a NOEC of 0.78 µg L−1 was 
achieved [126]. Isidori et al. [124] tested erythromycin, oxytetra- 
cyclin, sulfamethoxazole, ofloxacin, lincomycin and clarithromycin on 
aquatic organisms belonging to different trophic levels (bacte- ria, 
algae, rotifers, crustaceans and fish). Results showed that acute toxicity 
level was in the order of mg L−1 while chronic toxicity appeared at 
concentrations in the order of µg L−1, mainly for algae. The antibiotics 
tested were shown to be less active against rotifers, crustaceans and fish 
where no effect was noticed even for con- centrations up to 1000 mg 
L−1. After a 48 h exposure period of the microalga Scenedesmus 
obliquus to a concentration range of nor- floxacin between 0 and 60 mg 
L−1 was noticed a growth inhibition (EC50 = 38.49 mg L
−1) and a 
reduction in chlorophyll-a concentra- tion [127]. 
Most antibiotics used in veterinary medicine are aimed at 
preventing and treating diseases in livestock production or aquaculture. 
Even considering their use at sub-therapeutically con- centrations, many 
studies suggest the development of bacterial resistance and further 
potential appearance of cross-resistance between different classes of 
antibiotics shared with humans [43,58,120,128]. Antibiotics used in 
livestock production are excreted in the urine and faeces of animals 
and often appear in manure. From here they can cause some 
problems in terres- trial ecosystems such as adverse effects on  
nitrifying bacteria [11] or growth inhibition of crop plants and weeds 
by bioaccu- mulation [129]. The presence of antibiotics in STP 
influents may also impair treatment processes that use bacteria and 
cause toxic effects in the downstream aquatic and/or terrestrial 
ecosystems at different trophic levels [11]. Bacterial cultures from 
sewage bioreactors receiving waters from a STP were tested for 
resis- tance against six antibiotics, showing that all were resistant to at 
least two of the antibiotics, whilst bacteria isolated from receiv- ing 
waters were only resistant to erythromycin and ampicillin [130]. 
Aquatic photosynthetic organisms can also be affected. A study 
performed both on the cyanobacterium Synechocystis sp. and the 
duckweed L. minor showed growth inhibition in the presence of 1–
1000 µg L−1 erythromycin while another antibiotic, tetracycline, 
inhibited growth of the former when at concentra- tions between 10 
and 100 µg L−1 while stimulating  the latter [77]. Eguchi et al. [131] 
studied the influence of several antimi- crobial agents used as 
veterinary drugs in Japan on the growth of the green algae Selenastrum 
capricornutum and C. vulgaris by considering the growth inhibitory 
activity. Erithromycin showed 
lic health by means of treatment effectiveness [52,108]. According 
to Jones et al. [120], antibiotics could be classified as extremely the strongest activity against S. capricornutum with an EC50 value 
toxic to microorganisms (EC50 below 0.1 mg L
−1) and very toxic to 
algae (EC50 between 0.1 and 1 mg L
−1). Chronic toxicity tests 
performed on algae have shown high sensitivity to antibacte- rial 
agents as deduced from growth inhibition measurements [121,122]. 
Vertebrates (such as fish) put directly in contact with low levels of 
antimicrobials apparently did not yield observable effects [123,124]. 
Accordingly, a LC50 value above 100 mg L
−1 for Japanese medaka 
concerning sulfonamides was reported [81]. However, one must bear in 
mind that algae constitute the basis of the food chain and a decrease in 
their population will directly affect the entire aquatic ecosystem 
equilibrium [123,125]. Exposure of D. magna to erythromycin, 
lincomycin, sulfamethoxazole or  trimethoprim 
of 37 µg L−1 followed by dihydrostreptomycin (EC50 = 110 µg L
−1), 
oxytetracycline (EC50 = 340 µg L
−1) and tylosin (EC50 = 410 µg L
−1). 
Sulfonamides exhibited lower inhibitory activity with EC50 val- ues 
between 1.53 and 2.30 mg L−1. In contrast, ampicillin and cefalozin 
did not show any effect even at concentrations as high as 1000 mg L−1. 
The authors also showed the arousal of a synergis- tic inhibitory growth 
activity from the very common combination of sulfamethoxazole with 
trimethoprim in medicines, when com- pared to the respective 
individual activities. Yamashita et al. [132] evaluated the growth 
inhibition of the algae P. subcapitata by two antibiotics, 
levofloxacin and clarithromycin, showing that the last one had a more 
pronounced toxic effect with an EC50  of 
1  and a LOEC and a NOEC of 6.3 and 3.1 µgL 1, respec- 
in a concentration ranging from 1 to 100 µg L−1 did not affect the 
degree of survival, nor morphology in adults or neonates, nor fecun- 
 
 
 
6   NOEC—Non-Observed Effect Concentration. 
11 µg L− − 
tively. Toxic effects of sulfachlorpyridazine and oxytetracycline were  also  
tested  on  the  aquatic  plant  L.   minor,  showing    EC50 
values of 2.33 and 4.92 mg L−1, respectively [133]. Assays on   D. 
magna showed that following 48 h of exposure, oxolinic acid and 
tiamulin  were  the  most  toxic  compounds,  with  EC50   values   of 
  
 
Table 3 
Examples of concentrations (ng L−1 ) of antibiotics measured in different aquatic environments. 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
(Fluor)quinolones             
Ciprofloxacin 85721-33-1 Surface water USA SPE-LC–MS 20 20 [23]      
Ciprofloxacin  Po river Italy SPE- 0.3 ND–26.15 [24]      
  water  HPLC–MS/MS         
  Lambro river    14.36       
  water           
Ciprofloxacin  STP influent USA SPE- 20 ND–1000 [138]      
    HPLC–MS/MS         
  STP effluent    ND       
  Hospital    ND–2000       
  effluent           
  Rio Grande    ND       
  river water           
Ciprofloxacin  STP influent Portugal SPE-LC-FD 25 (LOQ) 418.8–667.1 [139]      
  STP effluent    100.8–309.2       
  Hospital    127.0–10,962.5       
  effluent           
Ciprofloxacin  STP influent USA SPE-LC–MS 50 150 [140]      
  STP effluent    60       
Ciprofloxacin  STP influent Sweden SPE-LC–MS 6 (LOQ) 90–300 [141]      
  STP effluent    <6–60       
Ciprofloxacin  Mondego Portugal SPE-LC-FD 25 79.6–119.2 [142]      
  river water           
Enrofloxacin 93106-60-6 STP influent Portugal SPE-LC-FD 50 (LOQ) 121.8–447.1 [139] Bacteria V. fischeri EC50  (15 min) 326.8 mg L
−1
 [13]6 
          (luminescence)   
  STP effluent    53.7–211.5       
  Hospital    <50       
  effluent           
Enrofloxacin  STP influent USA SPE-LC–MS 50 250 [140] Crustacean D. magna EC50  (24 h) 131.7 mg L
−1
 [136] 
          (immobilization)   
  STP effluent    270       
Enrofloxacin  Mondego Portugal SPE-LC-FD 25 67.0–102.5 [142]   EC50  (48 h) 56.7 mg L
−1
 [136] 
  river water        (immobilization)   
          EC50  (21 d) (adult 11.47 mg L
−1
 [136] 
          survival)   
          LOEC (21 d) 15 mg L
−1
 [136] 
          (reproduction)   
          NOEC (21 d) 5 mg L
−1
 [136] 
          (reproduction)   
         M. macrocopa EC50  (24 h) 285.7 mg L
−1
 [136] 
          (immobilization)   
Levofloxacin 100986-34-5 Mankyung 
river water 
South Korea SPE-LC–MS/MS 5 ND–87.4 (±13) [92] Crustacean T. platyurus LC50 (24 h) 
(mortality) 
>100 mg L−1 [78] 
        Fish O. latipes LC50 (96 h) >100 mg L
−1
 [78] 
          (mortality)   
        Algae P. subcapitata EC50 (96 h) (growth 1200 µg L
−1
 [132] 
          inhibition)   
          LOEC (96 h) (growth 630 µg L
−1
 [132] 
          inhibition)   
          NOEC (96 h) (growth 310 µg L
−1
 [132] 
          inhibition)   
        Crustacean D. magna EC50  (21 d) 340 µg L
−1
 [132] 
          (reproduction)   
          LOEC (21 d) 63 µg L
−1
 [132] 
          (reproduction)   
  
 
Table 3 (Continued ) 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
          NOEC (21 d) 31 µg L−1 [132] 
          (reproduction)   
Nalidixic acid 389-08-2 STP influent Taiwan SPE- HPLC–
MS/MS 
—† 26–372 [87]      
  STP effluent    40–200       
Norfloxacin 70458-96-7 Surface water USA SPE-LC–MS 20 120 [23] Algae S. obliquus IC50  (48 h) (growth 38.49 mg L
−1
 [127] 
          inhibition)   
Norfloxacin  STP influent Portugal SPE-LC-FD 25 (LOQ) 191.2–455.0 [139] Algae S. capricornutum EC50  (growth 16.6 mg L
−1
 [131] 
          inhibition)   
  STP effluent    29.6–35.0       
  Hospital    <25–334.0       
  effluent           
Norfloxacin  STP influent Sweden SPE-LC–MS 7 (LOQ) 72–174 [141]   NOEC (growth 4.01 mg L
−1
 [131] 
          inhibition)   
  STP effluent    <6–37       
Norfloxacin  Mondego Portugal SPE-LC-FD 25 ND [142]  C. vulgaris EC50  (growth 10.4 mg L
−1
 [131] 
  river water        inhibition)   
Norfloxacin  Surface China SPE- 13 <13–8.00 [144]   NOEC (growth 4.02 mg L
−1
 [131] 
  seawater  HPLC–MS/MS      inhibition)   
   (Hong Kong)          
Norfloxacin  Victoria China SPE-HPLC–MS 3.2 (LOQ seawater) 9.4–12.3 [145] Rotifer B. calyciflorus LC50 (24 h) 29.88 mg L
−1
 [124] 
  Harbour        (mortality)   
  seawater           
  Pearl River   10 (LOQ river water)        
  water           
      12–150       
Ofloxacin 82419-36-1 STP influent Taiwan SPE- HPLC–
MS/MS 
—† 115–1274 [87]   EC50  (48 h) 
(population growth 
0.53 mg L−1 [124] 
          inhibition)   
  STP effluent    53–991       
Ofloxacin  STP influent USA SPE- 10 ND–1000 [138] Crustacean T. platyurus LC50 (24 h) 33.98 mg L
−1
 [124] 
    HPLC–MS/MS      (mortality)   
  STP effluent    110       
  Hospital    ND–35,500       
  effluent           
  Rio Grande    ND       
  river water           
Ofloxacin  STP influent Portugal SPE-LC-FD 250 ND [139]  D. magna EC50  (24 h) 31.75 mg L
−1
 [124] 
          (immobilization)   
  STP effluent    ND       
  Hospital    ND–10,675.5       
  effluent           
Ofloxacin  STP influent Sweden SPE-LC–MS 6 (LOQ) <6–287 [141]  C. dubia EC50  (24 h) 17.41 mg L
−1
 [124] 
          (immobilization)   
  STP effluent    <6–52       
Ofloxacin  Victoria China SPE-HPLC–MS 2.6 (LOQ seawater) 5.2–10 [145]   EC50 (7 d) (population 3.13 mg L
−1
 [124] 
  Harbour        growth inhibition)   
  seawater           
  Pearl River   10 (LOQ river water)        
  water           
      11–77       
        Algae P. subcapitata EC50 (72 h) (growth 1.44 mg L
−1
 [124] 
          inhibition)   
Oxolinic acid 14698-29-4       Algae M. aeruginosa EC50 (72 h) (growth 0.180 mg L
−1
 [122] 
          inhibition)   
  
 
 
R. salina EC50 (72 h) (growth 
inhibition) 
 
10 mg L−1 [122] 
S. 
capricornutum 
EC50 (72 h) (growth 
inhibition) 
16 mg L−1 [122] 
Crustacean     D. magna EC50  (24 h) 
(immobilization) 
EC50  (48 h) 
(immobilization) 
NOEC (21 d) 
(reproduction) 
Sarafloxacin 98105-99-8 Algae R. salina EC50 (72 h) (growth 
inhibition) 
5.9 mg L−1 [134] 
 
4.6 mg L−1 [134] 
 
0.38 mg L−1 [134] 
 
24 mg L−1 [122] 
 
 
ˇ-Lactams 
S. 
capricornutum 
EC50 (72 h) (growth 
inhibition) 
16 mg L−1 [122] 
Amoxicillin 81030-75-3 Algae M. aeruginosa EC50 (72 h) (growth 
inhibition) 
0.0037 mg L−1  [122] 
S. 
capricornutum 
NOEC (72 h) (growth 
inhibition) 
250 mg L−1 [122] 
 
 
 
 
 
 
 
 
 
Ampicillin 69-53-4 Hospital effluent 
Pharmaceutical 
production 
facility 
effluent 
 
 
 
 
 
 
 
 
 
Taiwan SPE- HPLC–
MS/MS 
Algae S. leopoliensis EC50 (growth 
inhibition) 
NOEC (growth 
inhibition) LOEC 
(growth 
inhibition) 
Bacteria V. fischeri EC50  (15 min) 
(luminescence) 
10 21 [47] Bacteria V. fischeri EC50 (15 min) 
(luminescence) 
ND 
2.22 µg L−1 [126] 
 
0.78 µg L−1 [126] 
 
1.56 µg L−1 [126] 
 
3597 mg L−1 [136] 
 
2627 mg L−1 [136] 
Penicillin G (Benzylpenicillin)      69-57-8 STP influent China SPE-LC–MS 930 (LOQ)      153,000 ± 4000 [48] Algae M. aeruginosa EC50 (growth rate) 0.006 mg L
−1       [121] 
STP effluent    1680 ± 480 
 
 
Cephalosporins 
Cephalexin 66905-57-5       STP influent Taiwan SPE- HPLC–
MS/MS 
 
 
—† 1563–4367 [87] 
S. 
capricornutum 
NOEC (growth rate) 100 mg L−1 [121] 
STP effluent 10–994 
Cephalexin Surface 
seawater 
 
Lincosamide 
China SPE- 
HPLC–MS/MS 
(Hong Kong) 
13 <13–182 [144] 
Lincomycin 154-21-2 Surface water    USA SPE-LC–MS 50 60 [23] Rotifer B. calyciflorus LC50 (24 h) 
(mortality) 
24.94 mg L−1     [124] 
Lincomycin Po river 
water 
Italy SPE- 
HPLC–MS/MS 
0.3 3.13–248.90 [24] EC50 (48 h) 
(population growth 
inhibition) 
0.68 mg L−1 [124] 
Lambro river 
water 
24.40 
Lincomycin Groundwater USA SPE-LC–MS 50 320 [28] Crustacean     T. platyurus LC50 (24 h) 
(mortality) 
30.00 mg L−1     [124] 
Lincomycin Hospital 
effluent 
Livestock 
effluent 
USA SPE- 
HPLC–MS/MS 
10 ND–2000 [138] D. magna EC50 (24 h) 
(immobilization) 
ND–6600 
 
C. dubia EC50 (24 h) 
(immobilization) 
23.18 mg L−1     [124] 
 
 
 
13.98 mg L−1     [124] 
  
 
Table 3 (Continued ) 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
          EC50 (7 d) (population 7.20 mg L−1 [124] 
          growth inhibition)   
        Algae P. subcapitata EC50 (72 h) (growth 0.07 mg L
−1
 [124] 
          inhibition)   
Macrolides             
Clarithromycin 81103-11-9 Po river Italy SPE- 0.3 0.49–20.30 [24] Rotifer B. calyciflorus LC50 (24 h) 35.46 mg L
−1
 [124] 
  water  HPLC–MS/MS      (mortality)   
  Lambro river    8.31       
  water           
Clarithromycin  STP influent Taiwan SPE- HPLC–
MS/MS 
—† 59–1433 [87]   EC50  (48 h) 
(population growth 
12.21 mg L−1 [124] 
          inhibition)   
  STP effluent    12–232       
Clarithromycin  Mankyung 
river water 
South Korea SPE-LC–MS/MS 1 ND–443 (±14) [92] Crustacean T. platyurus LC50 (24 h) 
(mortality) 
94.23 mg L−1 [78] 
        Fish O. latipes LC50 (96 h) >100 mg L
−1
 [78] 
          (mortality)   
        Crustacean T. platyurus LC50 (24 h) 33.64 mg L
−1
 [124] 
          (mortality)   
         D. magna EC50  (24 h) 25.72 mg L
−1
 [124] 
          (immobilization)   
         C. dubia EC50  (24 h) 18.66 mg L
−1
 [124] 
          (immobilization)   
          EC50 (7 d) (population 8.16 mg L
−1
 [124] 
          growth inhibition)   
        Algae P. subcapitata EC50 (72 h) (growth 0.0020 mg L
−1
 [124] 
          inhibition)   
        Algae P. subcapitata EC50 (96 h) (growth 11 µg L
−1
 [132] 
          inhibition)   
          LOEC (96 h) (growth 6.3 µg L
−1
 [132] 
          inhibition)   
          NOEC (96 h) (growth 3.1 µg L
−1
 [132] 
          inhibition)   
        Crustacean D. magna EC50  (21 d) 40 µg L
−1
 [132] 
          (reproduction)   
          LOEC (21 d) 6.3 µg L
−1
 [132] 
          (reproduction)   
          NOEC (21 d) 3.1 µg L
−1
 [132] 
          (reproduction)   
Erithromycin 114-07-8 Po river Italy SPE- 0.3 1.40–15.90 [24] Duckweed Lemna minor EC50 (7 d) (growth 5.62 mg L
−1
 [77] 
  water  HPLC–MS/MS      inhibition)   
  Lambro river    4.50       
  water           
Erithromycin  STP effluent South Korea SPE-LC–MS/MS 1.0 8.9–294 [90] Crustacean T. platyurus LC50 (24 h) >100 mg L
−1
 [78] 
          (mortality)   
  Surface water    1.8–4.8       
Erithromycin  Mankyung 
river water 
South Korea SPE-LC–MS/MS 1 ND–137 (±15) [92] Fish O. latipes LC50 (96 h) 
(mortality) 
>100 mg L−1 [78] 
        Rotifer B. calyciflorus LC50 (24 h) 27.53 mg L
−1
 [124] 
          (mortality)   
          EC50  (48 h) 0.94 mg L
−1
 [124] 
          (population growth   
          inhibition)   
  
 
 
Crustacean     T. platyurus LC50 (24 h) 
(mortality) 
D. magna EC50 (24 h) 
(immobilization) 
C. dubia EC50  (24 h) 
(immobilization) 
EC50 (7 d) (population 
growth inhibition) 
Algae P. subcapitata EC50 (72 h) (growth 
inhibition) 
 
17.68 mg L−1     [124] 
 
22.45 mg L−1     [124] 
 
10.23 mg L−1     [124] 
 
0.22 mg L−1 [124] 
 
0.020 mg L−1     [124] 
Algae S. 
capricornutum 
EC50 (growth 
inhibition) 
NOEC (growth 
inhibition) 
0.0366 mg L−1  [131] 
 
0.0103 mg L−1  [131] 
 
 
 
 
Erithromycin-H2 O*   114-07-8 Hospital 
effluent 
Pharmaceutical 
production 
facility 
effluent 
 
 
 
 
Taiwan SPE- HPLC–
MS/MS 
 
 
 
 
1.0 938 [47] 
 
110 
C. vulgaris EC50 (growth 
inhibition) 
NOEC (growth 
inhibition) 
33.8 mg L−1 [131] 
 
12.5 mg L−1 [131] 
Erithromycin-H2 O* STP influent Taiwan SPE- HPLC–
MS/MS 
—† 226–1537 [87] 
STP effluent 361–811 
Erithromycin-H2 O* Surface 
seawater 
China SPE- 
HPLC–MS/MS 
(Hong Kong) 
13 9.50–486 [144] 
Erithromycin-H2 O* Victoria 
Harbour 
seawater 
Pearl River 
water 
China SPE-HPLC–MS 2.0 (LOQ seawater) 3.3–3.4 [145] 
 
 
5 (LOQ river water) 
 
30–460 
Roxithromycin 80214-83-1     Surface water    USA SPE-LC–MS 30 50 [23] 
Roxithromycin Victoria 
Harbour 
seawater 
Pearl River 
water 
China SPE-HPLC–MS 2.0 (LOQ seawater) 5.1–6.1 [145] 
 
 
5 (LOQ river water) 
 
16–66 
Spiramycin 67262-35-5       Po river water 
Lambro river 
water 
Italy SPE- 
HPLC–MS/MS 
0.3 ND–43.80 [24] Algae M. aeruginosa EC50 (growth rate) 0.005 mg L
−1       [121] 
 
74.20 
S. 
capricornutum 
EC50 (growth rate) 2.3 mg L
−1 [121] 
Tylosin 1401-69-0 Surface water   USA SPE-LC–MS 50 40 [23] Algae M. aeruginosa EC50 (growth rate) 0.034 mg L
−1     [121] 
Tylosin Po river 
water Lambro 
river water 
Italy SPE- 
HPLC–MS/MS 
0.3 ND–0.30 [24] S. 
capricornutum 
2.77 
EC50 (growth rate) 1.38 mg L
−1 [121] 
Algae S. 
capricornutum 
EC50 (growth 
inhibition) 
NOEC (growth 
inhibition) 
0.411 mg L−1     [131] 
 
0.206 mg L−1     [131] 
Crustacean      D. magna LOEC (24 h) 
(immobilization) 
700 mg L−1 [134] 
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          EC50  (48 h) 680 mg L−1 [134] 
          (immobilization)   
          NOEC (21 d) 45 mg L
−1
 [134] 
          (reproduction)   
Sulfonamides             
Sulfachloropyridazine 80-32-0 STP influent Korea SPE-LC–MS 30 <30–476 [93] Bacteria V. fischeri EC50  (15 min) 26.4 mg L
−1
 [82] 
  STP effluent    <30–149       
        Crustacean D. magna EC50  (48 h) 375.3 mg L
−1
 [82] 
          (immobilization)   
         D. magna EC50  (96 h) 233.5 mg L
−1
 [82] 
          (immobilization)   
        Fish O. latipes LC50 (48 h) 589.3 mg L
−1
 [82] 
         O. latipes LC50 (96 h) 535.7 mg L
−1
 [82] 
        Aquatic plant Lemna minor EC50 (48 h) (n
◦ of 2.33 mg L
−1
 [133] 
          green fronds)   
Sulfadiazine 68-35-9 Tevere river Italy SPE-LC–MS 21 (LOQ) 236 [143] Algae M. aeruginosa EC50 (72 h) (growth 0.135 mg L
−1
 [122] 
  water        inhibition)   
Sulfadiazine  Victoria China SPE-HPLC–MS 0.5 (LOQ seawater) ND [145]  S. EC50 (72 h) (growth 7.8 mg L
−1
 [122] 
  Harbour       capricornutum inhibition)   
  seawater           
  Pearl River   1 (LOQ river water)        
  water           
      38–209       
        Algae S. EC50  (growth 2.19 mg L
−1
 [131] 
         capricornutum inhibition)   
          NOEC (growth <1.00 mg L
−1
 [131] 
          inhibition)   
        Crustacean D. magna LOEC (24 h) 150 mg L
−1
 [132] 
          (immobilization)   
          EC50  (48 h) 221 mg L
−1
 [132] 
          (immobilization)   
          EC50  (21 d) 13.7 mg L
−1
 [132] 
          (reproduction)   
        Crustacean D. magna EC50  (48 h) 212 mg L
−1
 [135] 
          (immobilization)   
Sulfadimethoxine 122-11-2 Surface water USA SPE-LC–MS 50 60 [23] Bacteria V. fischeri EC50  (15 min) >500 mg L
−1
 [82] 
Sulfadimethoxine  Groundwater USA SPE-LC–MS/MS 30 46–68 [27] Crustacean D. magna EC50  (48 h) 248.0 mg L
−1
 [82] 
          (immobilization)   
Sulfadimethoxine  Hospital Taiwan SPE- 1.0 ND [47]  D. magna EC50  (96 h) 204.5 mg L
−1
 [82] 
  effluent  HPLC–MS/MS      (immobilization)   
  Pharmaceutical    0.8       
  production           
  facility           
  effluent           
Sulfadimethoxine  STP influent Luxembourg SPE-LC–MS/MS 0.3 0.3–26 [89] Fish O. latipes LC50 (48 h) >100 mg L
−1
 [82] 
  STP effluent    0.3–9       
  Alzette river    0.3–3       
  water           
  Mess river    <0.3       
  water           
Sulfadimethoxine  STP influent Korea SPE-LC–MS 10 <10–213 [93]  O. latipes LC50 (96 h) >100 mg L
−1
 [82] 
  STP effluent    <10–70       
  Han river    <10–13       
  water           
Sulfadimethoxine  Tevere river Italy SPE-LC–MS 8 28 [143] Algae S. EC50  (growth 2.30 mg L
−1
 [131] 
  water       capricornutum inhibition)   
  
 
 
 
 Trigno river 
water 
Drinking 
   74 
 
11 
 
water     
        NOEC (growth 0.529 mg L
−1
 [131] 
        inhibition)   
       C. vulgaris EC50  (growth 11.2 mg L
−1
 [131] 
        inhibition)   
        NOEC (growth <20.3 mg L
−1
 [131] 
        inhibition)   
      Crustacean D. magna EC50  (48 h) 270 mg L
−1
 [135] 
        (immobilization)   
      Crustacean D. magna EC50  (24 h) 639.8 mg L
−1
 [136] 
        (immobilization)   
       M. macrocopa EC50  (24 h) 296.6 mg L
−1
 [136] 
        (immobilization)   
        EC50  (48 h) 183.9 mg L
−1
 [136] 
        (immobilization)   
Sulfamethazine 57-68-1 Groundwater USA SPE-LC–MS/MS 20 76–215 [27] Bacteria V. fischeri EC50  (15 min) 344.7 mg L
−1
 [82] 
Sulfamethazine  Groundwater USA SPE-LC–MS 50 360 [28] Crustacean D. magna EC50  (48 h) 174.4 mg L
−1
 [82] 
          (immobilization)   
Sulfamethazine  Hospital Taiwan SPE- 0.5 ND [47]  D. magna EC50  (96 h) 158.8 mg L
−1
 [82] 
  effluent  HPLC–MS/MS      (immobilization)   
  Pharmaceutical    178       
  production           
  facility           
  effluent           
Sulfamethazine  STP influent Luxembourg SPE-LC–MS/MS 0.3 0.3–2 [89] Fish O. latipes LC50 (48 h) >100 mg L
−1
 [82] 
  STP effluent    <0.3       
  Alzette river    <0.3       
  water           
  Mess river    <0.3       
  water           
Sulfamethazine  STP influent USA SPE-LC–MS 50 160 [140]  O. latipes LC50 (96 h) >100 mg L
−1
 [82] 
  STP effluent    ND       
        Crustacean D. magna EC50  (48 h) 202 mg L
−1
 [135] 
          (immobilization)   
          EC50  (21 d) 4.25 mg L
−1
 [135] 
          (reproduction)   
          LOEC (21 d) 3.125 mg L
−1
 [135] 
          (reproduction)   
          NOEC (21 d) 1.563 mg L
−1
 [135] 
          (reproduction)   
        Crustacean D. magna EC50  (24 h) 506.3 mg L
−1
 [136] 
          (immobilization)   
          EC50  (48 h) 215.9 mg L
−1
 [136] 
          (immobilization)   
         M. macrocopa EC50  (24 h) 310.9 mg L
−1
 [136] 
          (immobilization)   
          EC50  (48 h) 110.7 mg L
−1
 [136] 
          (immobilization)   
Sulfamethoxazole 723-46-6 Surface water USA SPE-LC–MS 50 150 [23] Bacteria V. fischeri EC50  (15 min) 78.1 mg L
−1
 [82] 
Sulfamethoxazole  Groundwater USA SPE-LC–MS 23 1110 [28] Crustacean D. magna EC50  (48 h) 189.2 mg L
−1
 [82] 
          (immobilization)   
Sulfamethoxazole  Drinking USA SPE-LC–MS/MS 0.25 0.32 [32]  D. magna EC50  (96 h) 177.3 mg L
−1
 [82] 
  water        (immobilization)   
Sulfamethoxazole  Hospital Taiwan SPE- 1.0 1335 [47] Fish O. latipes LC50 (48 h) >750 mg L
−1
 [82] 
  effluent  HPLC–MS/MS         
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  Pharmaceutical    34       
  production           
  facility           
  effluent           
Sulfamethoxazole  STP influent Taiwan SPE- HPLC–
MS/MS 
—† 179–1760 [87]  O. latipes LC50 (96 h) 562.5 mg L
−1
 [82] 
  STP effluent    47–964       
Sulfamethoxazole  STP influent Luxembourg SPE-LC–MS/MS 0.3 13–155 [89] Cnidarian Hydra LC50 (96 h) >100 mg L
−1
 [98] 
         attenuata (morphology)   
  STP effluent    4–39       
  Alzette river    1–22       
  water           
  Mess river    0.3–5       
  water           
Sulfamethoxazole  STP effluent South Korea SPE-LC–MS/MS 1.0 3.8–407 [90]   LOEC (96 h) 10 mg L
−1
 [98] 
          (morphology)   
  Surface water    1.7–36       
Sulfamethoxazole  STP influent Korea SPE-LC–MS 5 156–984 [93]   NOEC (96 h) 5 mg L
−1
 [98] 
          (morphology)   
  STP effluent    25–492       
  Han river    <5–82       
  water           
Sulfamethoxazole  STP influent USA SPE- 12 ND–1000 [138] Bacteria V. fischeri EC50  (30 min) 23.3 mg L
−1
 [124] 
    HPLC–MS/MS      (luminescnce)   
  STP effluent    310       
  Hospital    ND–2100       
  effluent           
  Rio Grande    ND–300       
  river water           
Sulfamethoxazole  STP influent USA SPE-LC–MS 50 300 [140] Rotifer B. calyciflorus LC50 (24 h) 26.27 mg L
−1
 [124] 
          (mortality)   
  STP effluent    200       
Sulfamethoxazole  STP influent Sweden SPE-LC–MS 80 (LOQ) <80–674 [141]   EC50  (48 h) 9.63 mg L
−1
 [124] 
          (population growth   
          inhibition)   
  STP effluent    <80–304       
Sulfamethoxazole  Tevere river Italy SPE-LC–MS 9 402 [143] Crustacean T. platyurus LC50 (24 h) 35.36 mg L
−1
 [124] 
  water        (mortality)   
  Drinking    13–80       
  water           
Sulfamethoxazole  Victoria China SPE-HPLC–MS 0.8 (LOQ seawater) ND [145]  D. magna EC50  (24 h) 25.20 mg L
−1
 [124] 
  Harbour        (immobilization)   
  seawater           
  Pearl River   1 (LOQ river water)        
  water           
      37–134       
         C. dubia EC50  (24 h) 15.51 mg L
−1
 [124] 
          (immobilization)   
          EC50 (7 d) (population 0.21 mg L
−1
 [124] 
          growth inhibition)   
        Algae P. subcapitata EC50 (72 h) (growth 0.52 mg L
−1
 [124] 
          inhibition)   
        Algae S. EC50  (growth 1.53 mg L
−1
 [131] 
         capricornutum inhibition)   
  
 
 
 
   NOEC (growth 
inhibition) 
0.614 mg L−1 [131] 
Crustacean D. magna EC50  (48 h) 123.1 mg L
−1
 [136] 
  (immobilization)   
 M. macrocopa EC50  (24 h) 84.9 mg L
−1
 [136] 
  (immobilization)   
  EC50  (48 h) 70.4 mg L
−1
 [136] 
  (immobilization)   
Sulfapyridine 7238-91-7 Tevere river Italy SPE-LC–MS 12 <12–121 [143] Cnidarian Hydra LC50 (96 h) >100 mg L
−1
 [98] 
  water       attenuata (morphology)   
  Trigno river    66       
  water           
          EC50  (96 h) 21.61 mg L
−1
 [98] 
          (morphology)   
          LOEC (96 h) 5 mg L
−1
 [98] 
          (morphology)   
          NOEC (96 h) 1 mg L
−1
 [98] 
          (morphology)   
Sulfathiazole 72-14-0 STP influent Luxembourg SPE-LC–MS/MS 0.3 0.3–2 [89] Bacteria V. fischeri EC50  (15 min) >1000 mg L
−1
 [82] 
  STP effluent    <0.3       
  Alzette river    <0.3       
  water           
  Mess river    0.3–2       
  water           
Sulfathiazole  STP influent Korea SPE-LC–MS 30 <30–531 [93] Crustacean D. magna LOEC (21 d) 35 mg L
−1
 [136] 
          (reproduction)   
  STP effluent    <30       
          NOEC (21 d) 11 mg L
−1
 [136] 
          (reproduction)   
        Crustacean D. magna EC50  (48 h) 149.3 mg L
−1
 [82] 
          (immobilization)   
         D. magna EC50  (96 h) 85.4 mg L
−1
 [82] 
          (immobilization)   
        Fish O. latipes LC50 (48 h) >500 mg L
−1
 [82] 
         O. latipes LC50 (96 h) >500 mg L
−1
 [82] 
        Crustacean D. magna EC50  (24 h) 616.7 mg L
−1
 [136] 
          (immobilization)   
         M. macrocopa EC50  (24 h) 430.1 mg L
−1
 [136] 
          (immobilization)   
          EC50  (48 h) 391.1 mg L
−1
 [136] 
          (immobilization)   
Tetracyclines             
Chlortetracycline 57-62-5 Surface water USA SPE-LC–MS 100 420 [23] Algae M. aeruginosa EC50 (growth rate) 0.05 mg L
−1
 [121] 
Chlortetracycline  Hospital Taiwan SPE- 5.0 ND [47]  S. EC50 (growth rate) 3.1 mg L
−1
 [121] 
  effluent  HPLC–MS/MS     capricornutum    
  Pharmaceutical    5.7       
  production           
  facility           
  effluent           
        Bacteria V. fischeri EC50  (15 min) 13.0 mg L
−1
 [136] 
          (luminescence)   
        Crustacean D. magna EC50  (24 h) 380.1 mg L
−1
 [136] 
          (immobilization)   
          EC50  (48 h) 225 mg L
−1
 [136] 
          (immobilization)   
         M. macrocopa EC50  (24 h) 515 mg L
−1
 [136] 
          (immobilization)   
          EC50  (48 h) 272 mg L
−1
 [136] 
          (immobilization)   
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        Fish O. latipes LC50 (24 h) 
(mortality) 
LC50 (48 h) 
88.4 mg L−1 
 
78.9 mg L−1 
[136] 
 
[136] 
 
Oxytetracycline 
 
79-57-2 
 
Surface water 
 
USA 
 
SPE-LC–MS 
 
100 
 
340 
 
[23] 
 
Cnidarian 
 
Hydra 
(mortality) 
LC50 (96 h) 
 
>100 mg L−1 
 
[98] 
 
Oxytetracycline 
  
Po river 
 
Italy 
 
SPE- 
 
0.3 
 
ND–19.2 
 
[24] 
 attenuata (morphology) 
EC50  (96 h) 
 
40.13 mg L−1 
 
[98] 
  water  HPLC–MS/MS      (morphology)   
  Lambro river    14.35       
 
Oxytetracycline 
 water 
Hospital 
 
Taiwan 
 
SPE- 
 
2.0 
 
2.9 
 
[47] 
   
LOEC (96 h) 
 
100 mg L−1 
 
[98] 
  effluent  HPLC–MS/MS      (morphology)   
  Pharmaceutical    23       
  production           
  facility           
 
Oxytetracycline 
 effluent 
STP influent 
 
Luxembourg 
 
SPE-LC–MS/MS 
 
0.3 
 
0.3–7 
 
[89] 
   
NOEC (96 h) 
 
50 mg L−1 
 
[98] 
          (morphology)   
  STP effluent    0.3–5       
  Alzette river    0.3–2       
  water           
  Mess river    0.3–7       
  water       
Algae 
 
M. aeruginosa 
 
EC50 (72 h) (growth 
 
0.207 mg L−1 
 
[122] 
          
R. salina 
inhibition) 
EC50 (72 h) (growth 
 
1.6 mg L−1 
 
[122] 
          
S. 
inhibition) 
EC50 (72 h) (growth 
 
4.5 mg L−1 
 
[122] 
  
Bacteria 
capricornutum 
V. fischeri 
inhibition) 
EC50  (30 min) 
 
64.50 mg L−1 
 
[124] 
 
Rotifer 
 
B. calyciflorus 
(luminescnce) 
LC50 (24 h) 
 
34.21 mg L−1 
 
[124] 
  (mortality) 
EC50  (48 h) 
 
1.87 mg L−1 
 
[124] 
  (population growth   
 
Crustacean 
 
T. platyurus 
inhibition) 
LC50 (24 h) 
 
25.00 mg L−1 
 
[124] 
  
D. magna 
(mortality) 
EC50  (24 h) 
 
22.64 mg L−1 
 
[124] 
  
C. dubia 
(immobilization) 
EC50  (24 h) 
 
18.65 mg L−1 
 
[124] 
  (immobilization) 
EC50 (7 d) (population 
 
0.18 mg L−1 
 
[124] 
 
Algae 
 
P. subcapitata 
growth inhibition) 
EC50 (72 h) (growth 
 
0.17 mg L−1 
 
[124] 
 
Algae 
 
S. 
inhibition) 
EC50 (growth 
 
0.342 mg L−1 
 
[131] 
 capricornutum inhibition) 
NOEC (growth 
 
0.183 mg L−1 
 
[131] 
  
C. vulgaris 
inhibition) 
EC50 (growth 
 
7.05 mg L−1 
 
[131] 
  inhibition) 
NOEC (growth 
 
<3.58 mg L−1 
 
[131] 
  inhibition)   
  
 
 
 
 Aquatic plant 
 
Crustacean 
Lemna minor 
 
D. magna 
EC50 (48 h) (n
◦ of 
green fronds) 
LOEC (48 h) 
4.92 mg L−1 
 
100 mg L−1 
[133] 
 
[134] 
  (immobilization)   
  EC50  (21 d) 46.2 mg L
−1
 [134] 
  (reproduction)   
Bacteria V. fischeri EC50  (15 min) 87.0 mg L
−1
 [136] 
  (luminescence)   
Crustacean D. magna EC50  (24 h) 831.6 mg L
−1
 [136] 
  (immobilization)   
  EC50  (48 h) 621.2 mg L
−1
 [136] 
  (immobilization)   
 M. macrocopa EC50  (24 h) 137.1 mg L
−1
 [136] 
  (immobilization)   
  EC50  (48 h) 126.7 mg L
−1
 [136] 
  (immobilization)   
Fish O. latipes LC50 (24 h) 215.4 mg L
−1
 [136] 
  (mortality)   
  LC50 (48 h) 110.1 mg L
−1
 [136] 
  (mortality)   
Tetracycline 60-54-8 Surface water USA SPE-LC–MS 100 110 [23] Duckweed Lemna minor EC50 (7 d) (growth 1.06 mg L
−1
 [77] 
          inhibition)   
Tetracycline  Hospital Taiwan SPE- 2.0 89 [47] Algae M. aeruginosa EC50 (growth rate) 0.09 mg L
−1
 [121] 
  effluent  HPLC–MS/MS         
  Pharmaceutical    25       
  production           
  facility           
  effluent           
Tetracycline  STP influent Taiwan SPE- HPLC–
MS/MS 
—† 46–234 [87]  S. 
capricornutum 
EC50 (growth rate) 2.2 mg L
−1
 [121] 
  STP effluent    16–38       
Tetracycline  STP influent Luxembourg SPE-LC–MS/MS 0.3 0.3–85 [89] Crustacean D. magna NOEC (48 h) 340 mg L
−1
 [134] 
          (immobilization)   
  STP effluent    0.3–24       
  Alzette river    0.3–8       
  water           
  Mess river    0.3–7       
  water           
Tetracycline  STP influent USA SPE-LC–MS 50 520 [140]   EC50  (21 d) 44.8 mg L
−1
 [134] 
          (reproduction)   
  STP effluent    170       
Tetracycline  Surface China SPE- 13 <13–122 [144]      
  seawater  HPLC–MS/MS         
   (Hong Kong)          
Others             
Chloramphenicol 85666-84-8 Victoria China SPE-HPLC–MS 4.1 (LOQ seawater) ND [145]      
  Harbour           
  seawater           
  Pearl River   5 (LOQ river water)        
  water           
      41–127       
Metronidazole 99616-64-5 STP influent Taiwan SPE- HPLC–
MS/MS 
—† 1–294 [87] Crustacean D. magna LOEC(48 h) 
(immobilization) 
1000 mg L−1 [134] 
  STP effluent    10–126       
          NOEC (21 d) 250 mg L
−1
 [134] 
          (reproduction)   
Trimethoprim 738-70-5 Surface water USA SPE-LC–MS 30 150 [23] Bacteria V. fischeri EC50  (15 min) 176.7 mg L
−1
 [82] 
Trimethoprim  Drinking USA SPE-LC–MS/MS 0.25 <0.25 [32] Crustacean D. magna EC50  (48 h) 167.4 mg L
−1
 [82] 
  water        (immobilization)   
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Trimethoprim  Danube river Serbia SPE-LC–MS/MS 0.34 25 [84]  D. magna EC50  (96 h) 120.7 mg L−1 [82] 
  water        (immobilization)   
  Tamisˇ  river           
  water           
  Lake Ocˇaga    24       
  water           
  Groundwater           
      174       
      100       
Trimethoprim  STP influent Taiwan SPE- HPLC–
MS/MS 
—† 259–949 [87] Fish O. latipes LC50 (48 h) >100 mg L
−1
 [82] 
  STP effluent    203–415       
Trimethoprim  STP effluent South Korea SPE-LC–MS/MS 1.0 10–188 [90]  O. latipes LC50 (96 h) >100 mg L
−1
 [82] 
  Surface water    3.2–5.3       
Trimethoprim  STP influent Korea SPE-LC–MS 10 <10–496 [93] Cnidarian Hydra LC50 (96 h) >100 mg L
−1
 [98] 
         attenuata (morphology)   
  STP effluent    <10–174       
  Han river    <10–26       
  water           
Trimethoprim  STP influent USA SPE- 10 ND–1400 [138]   LOEC (96 h) >100 mg L
−1
 [98] 
    HPLC–MS/MS      (morphology)   
  STP effluent    180       
  Hospital    ND–5000       
  effluent           
  Rio Grande    ND       
  river water           
Trimethoprim  STP influent USA SPE-LC–MS 50 330 [140]   NOEC (96 h) >100 mg L
−1
 [98] 
          (morphology)   
  STP effluent    170       
Trimethoprim  Surface China SPE- 13 <13–21.8 [144] Algae M. aeruginosa EC50 (72 h) (growth 112 mg L
−1
 [122] 
  seawater  HPLC–MS/MS      inhibition)   
   (Hong Kong)          
         R. salina EC50 (72 h) (growth 16 mg L
−1
 [122] 
          inhibition)   
         S. EC50 (72 h) (growth 130 mg L
−1
 [122] 
         capricornutum inhibition)   
 Algae S. EC50  (growth 80.3 mg L
−1
 [131] 
 capricornutum inhibition)   
  NOEC (growth 25.5 mg L
−1
 [131] 
  inhibition)   
Crustacean D. magna EC50  (48 h) 149 mg L
−1
 [135] 
  (immobilization)   
Crustacean D. magna EC50  (24 h) 155.6 mg L
−1
 [135] 
  (immobilization)   
  EC50  (48 h) 92.0 mg L
−1
 [135] 
  (immobilization)   
 M. macrocopa EC50  (24 h) 144.8 mg L
−1
 [135] 
  (immobilization)   
  EC50  (48 h) 54.8 mg L
−1
 [135] 
  (immobilization)   
Crustacean D. magna LOEC (21 d) 20 mg L−1 [136] 
  (reproduction)   
  NOEC (21 d) 6 mg L
−1
 [136] 
  (reproduction)   
ND—Not detected; †—Data not available; SPE—Solid Phase Extraction; GC–MS—Gas Chromatography with Mass Spectrometry Detection; HPLC–MS/MS—High Performance Liquid Chromatography with Tandem Mass Spectrometry Detection; LC-FD—
Liquid Chromatography with Fluorescence Detection; LC–MS—Liquid Chromatography with Mass Spectrometry Detection; LC–MS/MS—Liquid Chromatography with Tandem Mass Spectrometry Detection. 
 4.6 and 40 mg L−1 respectively [134], while sulfamethazine had an 
EC50 of 202 mg L
−1 [135]. Reproduction was also impaired by 
oxytetracycline, sulfadiazine, tetracycline and tiamulin at concen- 
trations between 5 and 50 mg L−1. Oxolinic acid, streptomycin and 
tylosin were revealed to be lethal after long-term exposure [134]. 
Chronic toxicity effects were also observed on the reproduction of the 
crustacean D. magna, when were exposed to levofloxacin and 
clarithromycin, with EC50 values of 340 and 40 µg L
−1, respec- tively 
[132]. Eleven commonly used antibiotics were evaluated in organisms 
belonging to different trophic levels (V. fischeri, D. magna, Moina 
macrocopa, and O. latipes). Neomycin showed sig- nificant effects on 
D. magna (EC50 = 42.1 mg L
−1), M. macrocopa (EC50 = 34.1 mg L
−1) 
and O. latipes (LC50 = 80.8 mg L
−1) while beta- lactam antibiotics 
(ampicillin and amoxycillin) were the less toxic to all tested organisms 
[136]. Neomycin showed chronic toxicity by affecting the reproduction 
and adult survival of D. magna and M. macrocopa even at low mg L−1 
levels of exposure (EC50s of 0.09 and 
0.74 mg L−1, respectively). Other pharmaceuticals such as sulfathia- zole, 
trimethoprim and enrofloxacin also showed similar effects on those two 
cladocerans in a dose-dependent manner. Luminescence inhibition on V. 
fischeri occurred after irradiation of tetracycline, proving that 
photolytic products become more toxic than the par- ent compound 
[137]. Antibiotics belonging to different classes have been found in 
different aquatic environments (Table 3). Lincomycin was detected in 
hospital and livestock effluents at concentrations of 2 and 6.6 µg L−1, 
respectively [138]. Fluorquinolone antibiotics as ciprofloxacin were 
found in hospital effluents [138,139] at val- ues between 2 and 11 µg 
L−1, in STP influents (90–1000 ng L−1) and effluents (<6–310 ng L−1) 
[138–141] as well as in surface waters, i.e. the Lambro river (Italy) 
(14.36 ng L−1) [24] and Mon- dego river (Portugal) (79.6–119.2 ng 
L−1) [142]. Enrofloxacin, a fluorquinolone used by the veterinary 
medicine, was detected in STP influents (121.8–447.1 ng L−1) and 
effluents (53.7–270 ng L−1) in Portugal [139] and the US [140] as well as 
in surface waters from the Mondego river (Portugal) (67.0–102.5 ng 
L−1) [142]. Sulfon- amides have been found in several aquatic systems as 
STP influents and effluents [138,140,141], surface waters [23,143], 
groundwa- ters [27,28] and drinking waters [143] in concentrations 
ranging from ng L−1 to a few µg L−1. Regarding the tetracyclines, 
oxyte- tracycline was detected in the Po and Lambro rivers (Italy) 
at concentrations up to 248.90 and 24.40 ng L−1 respectively  [24], in 
combination with tetracycline [140] in American STP influent (47 µg 
L−1) and effluent (4.2 µg L−1) [140] and in surface waters (340 ng L−1) 
[23]. In addition to aquatic systems, antibiotics belong- ing to the 
fluorquinolones class have also been found in sediments at 
concentrations that can reach 4.8 mg kg−1 [141]. This finding may 
represent a potential risk warning of persistence in the environ- ment. 
 
4.4. Sex hormones 
 
Sex hormones are extremely active biological compounds 
producing intense therapeutic effects even at very low doses. 
Today, they are commonly prescribed as oral contraceptives thus 
indirectly contributing to the increase in environmental concen- 
trations [52,108]. Estrogens are the sex hormones most commonly 
found in the environment. These can exist as either natural or 
synthetic substances, mimicking the effects of endogenous estro- gens 
as endocrine-disrupting compounds (EDCs) [146] through binding to 
specific receptors common to non-target organisms (invertebrates, 
fish, reptiles, birds and mammals) [108]. In fish, estrogens are 
involved in several physiological functions includ- ing: (i) 
vitellogenin synthesis; (ii) vitelline envelope (eggshell) protein 
production; (iii) gonadal differentiation; (iv) development of secondary 
sexual characteristics; (v) gonadotropin    secretion; 
(vi) synthesis of estrogen receptors; (vii) pheromonal  communi- 
 
cation; (viii) bone formation; and (ix) calcium homeostasis [146]. The 
enhanced production of the vitellogenin found in the blood of male and 
juvenile fish provides a useful biomarker of aquatic con- tamination by 
compounds with estrogenic activity [52,146]. Wild fish (roach; Rutilus 
rutilus) exposed to such compounds in UK rivers receiving STP effluents 
suffered adverse reproductive effects. Male fish were shown to be intersex, 
i.e. they had simultaneous male and female gonadal characteristics 
besides a high plasma vitellogenin concentration [147]. Ethinylestradiol 
(EE2) is a synthetic estrogen found in oral contraceptive pills with 
marked estrogenic effects in fish. The life-cycle exposure of fathead 
minnows to EE2 concentra- tions below 1 ng L
−1 caused a significant 
reduction in fertilization success, an increased egg  production  and  
decreased  expression of secondary male sex characteristics [148]. 
Similar findings were obtained by Pawlowski et al. [149] in trials 
extended over a reduced period of three weeks. Concentrations below 1 
ng L−1 gave rise to an increased female population and for EE2  
concentrations    above 
3.5 ng L−1, fish became completely feminized [148]. Concentrations 
above 1 ng L−1 of EE2 also induced higher vitellogenin plasma lev- els in 
both males and females [149,150]. Nash et al. [151] registered similar 
findings for zebrafish males by simply performing the assay with 0.5 ng 
L−1 of EE2. Life-long exposure of zebrafish to 5 ng L
−1 of EE2 has led 
to reproductive failure due to the absence of sec- ondary male sex 
characteristics and normal testes [151]. Exposure of juveniles to 
estrogen has caused skewed sex ratios in favour of females for 
concentrations of 1 ng L−1 [150]. Sex reversal was complete at levels 
of 2 ng L−1 [150]. Xu et al. [152] also exposed zebrafish to EE2 during 
their period of sex differentiation, show- ing that, after 90 days post-
hatch, there was already an increase in mortality rate and sex ratio for 
fish exposed to concentrations of 2 ng L−1. When the concentration 
was increased to 10 ng L−1 was observed a significantly decrease in 
the weight and length body. On the other hand, 180 days post-hatch 
were found abnor- mal testicular morphologies in male fish, namely 
malformations of the sperm duct, an altered proportion of germ cell 
types, and a reduced number of spermatozoa, for those levels of EE2 
[152]. Exposure of male roach to EE2 concentrations up to 4 ng L
−1 in 
early life disrupted normal sexual development causing a femi- nized 
response, characterized by the presence of an ovarian cavity and induced 
plasma vitellogenin production [153]. Kidd et al. [34] conducted a 7-
year, whole-lake experiment, proving that chronic exposure of fathead 
minnow to concentrations of EE2 in the order of 5–6 ng L
−1, led to 
feminization of males fish, through produc- tion of vitellogenin and 
disruption in gonadal development, causing intersex, and altered 
oogenesis in females. Those reproductive alterations led to a collapse of 
the fathead minnow population due to the loss of the young generations, 
expressed in a loss of smaller sizes classes of fish, what contribute, in 
a last case, to leave this species from the lake near of extinction [34]. 
The natural estrogen 17�-estradiol (E2) can also negatively affect fish 
at low concentra- tions. Japanese medaka exposed to 33.5 ng L−1 of this 
estrogen in early life enhanced their body length and body weight. 
Addition- ally, the males also exhibited testis-ova after 14 days of 
exposure [154]. When the E2 concentration was increased to 140.6 ng 
L−1, testis-ova were observed in males (after 12 days exposure) and 
complete gonadal transformation to an ovary occurred after 20 days 
[154]. The exposure of adult fish to concentrations from 29.3 to 463 ng 
L−1 over 21 days gave rise to testis-ova development and induced 
vitellogenin production in males to all tested con- centrations [155]. 
At the higher level, a decrease in the number of eggs produced and 
fertility [155] was also observed. Amphib- ians and reptiles exposed to 
environmental estrogens showed sex reversal as well as significant 
changes in secondary sex character- istics [156,157]. Concerning 
invertebrates such as the amphipod Hyalella azteca it was observed 
that at sub-lethal concentrations of EE2  (0.1–10 µg L
−1) sexual 
development of males was affected 
  
 
Table 4 
Examples of concentrations (ng L−1 ) of sex hormones measured in different aquatic environments. 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
Diethylstilbestrol 8053-00-7 River water China SPME-GC–MS 2 20 (±0) [162]      
17a-Estradiol 57-91-0 Surface water USA LLE-GC–MS 5 30 [23]      
17a-Estradiol  Groundwater France SPE-LC–MS/MS 0.03 0.8–3.5 [164]      
17�-Estradiol 50-28-2 Surface water USA LLE-GC–MS 5 9 [23] Fish O. latipes NOEC (21 d) <29.3 ng L−1 [15]5 
          (testis-ova induction)   
17�-Estradiol  Drinking USA SPE-LC–MS/MS 0.50 <0.50 [32]   LOEC (21 d) <26.3 ng L
−1
 [155] 
  water        (testis-ova induction)   
17�-Estradiol  Hospital Taiwan SPE- 25 25 [47]   NOEC (21 d) (VTG 29.3 ng L
−1
 [155] 
  effluent  HPLC–MS/MS      induction)   
  Pharmaceutical    ND       
  production           
  facility           
  effluent           
17�-EStradiol  STP influent Japan SPE-GC–MS 0.1 (LOQ) 13.3–25.8 [86]      
  STP effluent    0.49–12.4       
17�-Estradiol  Pearl Rivers 
water 
China SPE-GC–MS 0.3 ND–7.5 (±0.4) [88]      
17�-Estradiol  STP influent Luxembourg SPE-LC–MS/MS 1.0 1.0–102 [89]      
  STP effluent    1.0–85       
  Alzette river    1.0–35       
  water           
  Mess river    1.0–6       
  water           
17�-Estradiol  STP effluent South Korea SPE-LC–MS/MS 1.0 <1.0 [90]      
  Surface water    ND       
17�-Estradiol  STP effluent Japan SPE-LC–MS/MS 0.3 0.3–2.5 [160]      
  Tamagawa    0.6–1.0       
  river water           
  Kasumigaura           
  lake water           
      <0.3       
17�-Estradiol  STP influent 
STP effluent 
Berlin surface 
Germany SPE-LC–MS/MS 2.0 (LOQ STP influent) 
0.4 (LOQ STP effluent) 
0.2 (LOQ surface water) 
11.8 (±5.1) 
0.8 (±0.3) 
<0.2 
[161]      
  water           
17�-Estradiol  River water China SPME-GC–MS 9 100 (±20) [162]      
17�-Estradiol  STP influent Italy SPE-LC–MS/MS 1.9 (STP influent) 10–31 [163]      
  STP effluent   0.8 (STP effluent) 3–8       
  Tibre river   0.2 (Tibre river water) 2–6       
  water           
17�-Estradiol  Groundwater France SPE-LC–MS/MS 0.01 0.3–1.3 [164]      
Estriol 50-27-1 Surface water USA LLE-GC–MS 5 19 [23]      
Estriol  STP influent Japan SPE-GC–MS 0.2 (LOQ) 83.0–255 [86]      
  STP effluent    0.31–0.84       
Estriol  STP effluent South Korea SPE-LC–MS/MS 5.0 8.9–25 [90]      
  Surface water    ND       
Estriol  STP influent Italy SPE-LC–MS/MS 7.0 (STP influent) 23–48 [163]      
  STP effluent   0.5 (STP effluent) ND–1       
  Tibre river   0.3 (Tibre river water) 2–5       
  water           
Estrone 53-16-7 Surface water USA LLE-GC–MS 5 27 [23]      
Estrone  Drinking USA SPE-LC–MS/MS 0.20 <0.20 [32]      
  water           
  
 
 
 
 
Estrone 
 
 
 
 
 
 
Estrone 
 Hospital effluent 
Pharmaceutical 
production 
facility 
effluent 
STP influent 
Taiwan 
 
 
 
 
 
 
Japan 
SPE- HPLC–
MS/MS 
 
 
 
 
 
SPE-GC–MS 
25 
 
 
 
 
 
 
0.6 (LOQ) 
126 
 
ND 
 
 
 
 
28.7–197 
[47] 
 
 
 
 
 
 
[86] 
 
  STP effluent    2.80–110  
Estrone  Pearl Rivers 
water 
China SPE-GC–MS 0.2 ND–75.0 (±5.3) [88] 
Estrone  STP influent Luxembourg SPE-LC–MS/MS 0.3 0.3–9 [89] 
  STP effluent    0.3–14  
  Alzette river    0.3–6  
  water      
  Mess river    0.3–27  
  water      
Estrone  STP effluent South Korea SPE-LC–MS/MS 1.0 2.2–36 [90] 
  Surface water    1.7–5.0  
Estrone  STP effluent Japan SPE-LC–MS/MS 0.1 2.5–34 [160] 
  Tamagawa    3.4–6.6  
  river water      
  Kasumigaura      
  lake water      
      0.2–0.8  
Estrone  STP influent 
STP effluent 
Berlin surface 
water 
Germany SPE-LC–MS/MS 1.0 (LOQ STP influent) 
0.2 (LOQ STP effluent) 
0.1 (LOQ surface water) 
188 (±92) 
12.6 (±7.0) 
0.16 (± 0.05) 
[161] 
Estrone  River water China SPME-GC–MS 18 180 (±20) [162] 
Estrone  STP influent Italy SPE-LC–MS/MS 1.2 (STP influent) 15–60 [163] 
  STP effluent   0.8 (STP effluent) 5–30  
  Tibre river   0.1 (Tibre river water) 5–12  
  water      
Estrone  Surface water France SPE-LC–MS/MS 0.02 0.3 [164] 
  Groundwater    0.8–3.5  
17a-Ethinylestradiol 57-63-6 Surface water USA LLE-GC–MS 5 73 [23] Fish P. promelas LOEC (21 d) (plasma 1 ng L−1 [149] 
          VTG induction)  
17a-Ethinylestradiol  Drinking USA SPE-LC–MS/MS 1.0 <1.0 [32]   LOEC (21 d) 1 ng L
−1
 [149] 
  water        (ultrastructure testes)  
17a-Ethinylestradiol  Hospital Taiwan SPE- 25 32 [47]   LOEC (21 d) 1 ng L
−1
 [149] 
  effluent  HPLC–MS/MS      (ultrastructure liver)  
  Pharmaceutical    ND      
  production          
  facility          
  effluent          
17a-Ethinylestradiol  STP influent Luxembourg SPE-LC–MS/MS 2.0 2.0–24 [89]   LOEC (21 d) 10 ng L
−1
 [149] 
          (fertilization rate)  
  STP effluent    <2.0      
  Alzette river    <2.0      
  water          
  Mess river    <2.0      
  water          
17a-Ethinylestradiol  STP effluent South Korea SPE-LC–MS/MS 1.0 1.3 [90] Fish D. rerio LOEC (38 dph) 2 ng L
−1
 [150] 
          (plasma VTG  
          induction)  
  
 
[158]. On the other hand, the estrogens E2 and EE2 did not show 
significant effects on reproduction or survival of C. dubia even at 
concentrations of 1 and 0.5 mg L−1, respectively [159]. According to 
many authors, the concentrations of estrogens detected in the 
environment may not post a threat to humans. However regard- ing 
these compounds, there is the possibility of bioaccumulation within 
aquatic organisms, thereby reaching humans through the food chain or 
directly through drinking water [146]. Estrogens have been found in 
water samples (Table 4) at low ng L−1 concentra- tions but they 
represent a greater risk for non-target organisms as already proved. For 
example, 17�-estradiol was detected in rivers [23,160–163] at levels 
ranging from 0.6 to 100 ng L−1 and in STP effluents at concentrations 
between 0.3 [160] and 85 ng L−1 [89]. Ethinylestradiol was also found 
in surface waters in the US (73 ng L−1) [23] and Italy (the Tibre river) at 
1 ng L−1 [163]. 
 
 
4.5. Antiepileptics 
 
Antiepileptic drugs act in the central nervous system (CNS) by 
reducing the overall neuronal activity. This can be achieved either by 
blocking voltage-dependent sodium channels (e.g. car- bamazepine) or 
by enhancement  of  the  inhibitory  effects  of the )'-aminobutyric acid 
(GABA) neurotransmitter (e.g. benzodi- azepines) [99]. 
Carbamazepine is carcinogenic to rats but does not have mutagenic 
properties in mammals [165]. Moreover, this drug is lethal to 
zebrafish at the 43 µg L−1 level and produces sub-lethal changes in 
Daphnia sp. at 92 µg L−1 [165]. Regarding aquatic organisms, it can be 
deduced that carbamazepine does have harmful proclivity since most of 
the acute toxicity data were har- vested from trial concentrations 
between 10 and 100 mg L−1 [98]. In fact, D. magna growth was shown 
to be sensitive to this com- pound, being inhibited for concentrations of 
carbamazepine above 
12.7 mg L−1 and with acute toxicity being evident at 17.2 mg L−1 [165]. 
The EC50 value (considering the motility as indicator) was 
approximately 13.8 mg L−1 after 48 h of exposure [96]. Female D. 
pulex exposed to 1 µg L−1 of carbamazepine showed a tendency to 
mature and reproduce earlier (with more offspring), suggesting that this 
pharmaceutical may slightly induce stimulatory effects [166]. For C. 
dubia, chronic toxicity studies revealed a NOEC of 25 µg L−1 [96] 
while the activity of G. pulex was slightly reduced by exposure to a 
concentration range from 1 to 10 ng L−1 [76]. Continuous exposure of 
H. attenuata to carbamazepine caused a significant reduction in 
feeding, with an EC50 of 3.76 mg L
−1 [98]. Japanese medaka showed a 
LC50 of 35.4 mg L
−1 [82] and ultrastruc- tural changes in the liver, 
kidney and gill tissues of carps were induced by this pharmaceutical 
[97]. The changes observed in the kidney were shown to occur as a 
cellular response to impaired kidney function. In gills, the effects were 
more pronounced for con- centrations above 20 µg L−1. Another 
important issue concerning carbamazepine is that it can adsorb to 
sediments, in this way threat- ening aquatic organisms which feed on 
organic matter. Oetken et al. [167] showed that exposure of the 
invertebrate Chironomus ripar- ius to this pharmaceutical through 
sediments caused a blockade of pupation and decreased emergence with 
EC50 values of 160 and 280 µg kg
−1 of dry weight, respectively. 
Carbamazepine is ubiq- uitously present in the environment, having 
an extremely low removal rate in STPs (7%) [54] and consequently 
being detected in rivers [16,20,21,54,92] at concentrations up to 595 
ng L−1 [92] (Table 5). In addition to surface waters, carbamazepine has 
also been found in groundwater [26,119] at concentrations that can 
reach 900 ng L−1. A monitoring programme performed on the river Rhine 
(Germany) over a decade, showed the regular detection of 
carbamazepine, with an annual average concentration of 100 ng L−1 [168]. 
These results support the idea that the presence of carba- mazepine in 
the environment may represent a real threat. 
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Table 5 
Examples of concentrations (ng L−1 ) of antiepileptic drugs measured in different aquatic environments. 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
Carbamazepine 298-46-4 STP influent Spain SPE-GC–MS 30 120–310 [14] Crustacean D. magna EC50  (48 h) >100 mg L
−1
 [65] 
          (immobilization)   
  STP effluent    110–230       
Carbamazepine  STP influent Finland SPE- 1.4 290–400 [16] Algae D. subspicatus EC50 (growth 74 mg L
−1
 [65] 
    HPLC–MS/MS      inhibition)   
  STP effluent    380–470       
  Vantaa river    <1.4–66       
  water           
  Luhtajoki    23       
  river water           
Carbamazepine  Somes river 
water 
Romania SPE-GC–MS 30 <30–75.1 (±6.1) [20] Duckweed L. minor EC50 (7 d) (growth 
inhibition) 
25.5 mg L−1 [65] 
Carbamazepine  STP influent Sweden SPE-LC–MS/MS —† 1680 [21] Crustacean Gammarus 
pulex 
LOEC (behaviour) 10 ng L−1 [76] 
  STP effluent    1180       
  Höje river    <1–500       
  water           
Carbamazepine  Groundwater Germany SPE-GC–MS 32 900 [26] Crustacean T. platyurus LC50 (24 h) (mortality) >100 mg L
−1
 [78] 
Carbamazepine  Drinking USA SPE-LC–MS/MS 0.5 6.8 [32] Fish O. latipes LC50 (96 h) (mortality) 45.87 mg L
−1
 [78] 
  water           
Carbamazepine  STP effluent Germany SPE-LC–MS/MS 50 (STP effluent) 2100 [54] Bacteria V. fischeri EC50  (15 min) 52.2 mg L
−1
 [82] 
  Surface water   30 (surface water) 250       
Carbamazepine  Hospital Spain SPE- 7 30–70 [73] Crustacean D. magna EC50  (48 h) >100 mg L
−1
 [82] 
  effluent  HPLC–MS/MS      (immobilization)   
Carbamazepine  Danube river Serbia SPE-LC–MS/MS 0.27 8–130 [84]  D. magna EC50  (96 h) 76.3 mg L
−1
 [82] 
  water        (immobilization)   
  Sava river    29–50       
  water           
  Tamisˇ  river    30       
  water           
  Lake Ocˇaga    30       
  water           
  Groundwater    6–23       
Carbamazepine  STP influent Japan SPE-GC–MS 6 14.9–270 [86] Fish O. latipes LC50  (48 h) 35.4 mg L
−1
 [82] 
  STP effluent    10.8–163       
Carbamazepine  STP influent Taiwan SPE- HPLC–
MS/MS 
—† 82–357 [87]  O. latipes LC50  (96 h) 35.4 mg L
−1
 [82] 
  STP effluent    93–214       
Carbamazepine  STP effluent South Korea SPE-LC–MS/MS 1.0 73–729 [90] Bacteria V. fischeri EC50  (30 min) >81,000 µg L
−1
 [96] 
  Surface water    4.5–61       
  Drinking    <1.0       
  water           
Carbamazepine  Mankyung 
river water 
South Korea SPE-LC–MS/MS 1 ND–595 (±14) [92] Algae P. subcapitata NOEC (96 h) (growth 
inhibition) 
>100,000 µg L−1 [96] 
Carbamazepine  STP influent Korea SPE-LC–MS 5 <5–451 [93]   LOEC (96 h) (growth >100,000 µg L
−1
 [96] 
          inhibition)   
  STP effluent    <5–195       
  Han river    <5–36       
  water           
Carbamazepine  STP effluent Italy SPE- 1.3 ND–1318 [118] Crustacean D. magna EC50  (48 h) >13,800 µg L
−1
 [96] 
    HPLC–MS/MS      (immobilization)   
Carbamazepine  Groundwater Germany SPE-GC–MS 2 (LOQ) 45 [119]  C. dubia EC50  (48 h) 77,700 µg L
−1
 [96] 
          (immobilization)   
Carbamazepine  STP influent France SPE-LC–MS 2.4 193–420 [169]   NOEC (7 d) 25 µg L
−1
 [96] 
STP effluent 86–258 
(reproduction) 
  
 
4.6. Beta-blockers 
 
Beta-blockers act by competitive inhibition of beta-adrenergic 
receptors, a class of receptors critical for normal functioning in the 
sympathetic branch of the vertebrate autonomic nervous sys- tem in 
vertebrates. Within the most commonly used �-blockers propranolol 
is a non-specific antagonist, blocking both �1      and 
�2-receptors while metoprolol and atenolol present �1-receptors 
specificity [99]. Fish, like other vertebrates, possess �-receptors in the 
heart, liver and reproductive system [170,171] so that pro- longed 
exposure to drugs belonging to this therapeutic class may cause 
deleterious effects. From a two weeks study, it was observed 
that exposure to 500 µg L−1  of propranolol reduced growth rates of 
Japanese medaka [172]. Plasma steroid levels were altered in both male 
and female fish even at concentrations as low as 1 µg L−1 pro- pranolol. 
Exposure to concentrations of 0.5 and 1 µg L−1 resulted 
in a decreased egg production. On the other hand, acute expo- sure 
of rainbow trout to 70.9 µg L−1 of propranolol showed no significant 
reduction in its heart rate [173]. However, for con- centrations of 
metoprolol of 1 µg L−1, ultrastructural changes in the liver and 
kidney were observed as well in gills if the con- centration rose 
above 20 µg L−1 [97]. Fathead minnows exposed to atenolol during 
embryo-larval development showed NOEC and LOEC values for growth 
rate of 3.2 and 10 mg L−1, respectively [174]. Furthermore, a reproduction 
study performed in adults over a 21- day exposure period demonstrated 
that the male fish condition index was the most sensitive endpoint with 
NOEC and LOEC val- ues of 1.0 and 3.2 mg L−1, respectively [174]. 
These data suggest that atenolol has a low chronic toxicity to fish when 
compared to propranolol. 
As invertebrates do not possess �-receptors a different poten- tial 
impact on these organisms would be expected. Accordingly, the acute 
toxicity of propranolol, metoprolol and nadolol was assessed on the 
invertebrates H. azteca, D. magna, D. lumholtzi and C. dubia. 
Following a 48-h exposure to propranolol, LC50  values of 29.8, 
1.6 and 0.8 mg L−1  were obtained for H. azteca, D. magna and   C. 
dubia respectively [172] while acute exposure to nadolol did not affect 
the survival of the invertebrates [172]. Regarding meto- prolol, D.  
magna  and C.  dubia  exhibited LC50  values of 63.9 and 
8.8 mg L−1, respectively [172]. However, Cleuvers [175] obtained a 
higher EC50 value (438 mg L
−1) in an acute toxicity test performed on D. 
magna. Reproduction in invertebrates decreased following propranolol 
exposure with NOEC values of 1 and 125 µg L−1 for 
H. azteca and C. dubia respectively [172]. Propranolol inhibited the 
growth of the green algae Desmodesmus subspicatus, showing an EC50 
of 7.7 mg L−1 [175] while atenolol almost failed to reg- ister a toxic 
effect (EC50 of 620 mg L
−1). Chronic exposure of D. magna to 
propranolol (9 days) resulted in a significant reduction in heart rate, 
fecundity and biomass with LOECs values of 55, 110 and 440 µg L−1 
respectively [176] while chronic exposure to meto- prolol showed 
LOECs of 12.5 mg L−1 (body mass) and 6.15 mg L−1 (reproduction). At 
the highest concentrations (25 and 50 mg L−1) reproduction ceased and 
at the highest levels, all organisms died before the end of the test. A 
reduced heart rate for D. magna was evident for a 3.2 mg L−1 level of 
metoprolol. Chronic toxicity tests performed in algae also evidenced 
their sensitivity to �-blockers with NOEC values below 1 mg L−1 [52]. 
Collectively, this data might indicate a possible environmental risk 
since propranolol has been detected in STP effluents [21,53,94] at 
concentrations from 30 to 373 ng L−1 and in surface waters 
[21,53,92,94] at levels of ng L−1 (Table 6). This pharmaceutical has 
also been found in hospital effluent (Spain) at concentrations that can 
reach 6.5 µg L−1 [73]. Other �-blockers such as atenolol, metoprolol 
and solatol have also been detected in environmental samples 
[16,21,24,73,118] including groundwater [26] at concen- trations up to 
122 µg L−1. T
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Table 6 
Examples of concentrations (ng L−1 ) of �-blockers agents measured in different aquatic environments. 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
Acebutolol 37517-30-9 STP influent Finland SPE- 0.8 390–510 [16]      
    HPLC–MS/MS         
  STP effluent    80–230       
  Vantaa river    <0.8–8       
  water           
  Luhtajoki    8       
  river water           
Atenolol 29122-68-7 STP influent Finland SPE- 11.8 510–800 [16] Crustacean T. platyurus LC50 (24 h) >100 mg L
−1
 [78] 
    HPLC–MS/MS      (mortality)   
  STP effluent    40–440       
  Vantaa river    <11.8–25       
  water           
  Luhtajoki    <11.8       
  river water           
Atenolol  STP influent Sweden SPE-LC–MS/MS —† 30 [21] Fish O. latipes LC50 (96 h) 
(mortality) 
>100 mg L−1 [78] 
  STP effluent    160       
  Höje river    10–60       
  water           
Atenolol  Po river Italy SPE- 0.3 (LOQ) 3.44–39.43 [24] Algae D. subspicatus EC50  (growth 620 mg L
−1
 [17]5 
  water  HPLC–MS/MS      inhibition)   
  Lambro river    241       
  water           
Atenolol  Drinking USA SPE-LC–MS/MS 0.25 0.47 [32] Crustacean D. magna EC50  (48 h) 313 mg L
−1
 [175] 
  water        (immobilization)   
Atenolol  Hospital Spain SPE- 28 100–122,000 [73] Fish P. promelas NOEC (28 d) (growth) 3.2 mg L
−1
 [174] 
  effluent  HPLC–MS/MS         
Atenolol  Mankyung 
river water 
South Korea SPE-LC–MS/MS 30 ND–690 (±26) [92]   LOEC (28 d) (growth) 10 mg L
−1
 [174] 
Atenolol  STP influent Taiwan SPE- HPLC–
MS/MS 
—† 738–2883 [87]   NOEC (21 d) 
(condition index) 
1.0 mg L−1 [174] 
  STP effluent    210–681       
Atenolol  STP effluent Italy SPE- 1.07 (LOQ) 27–1168 [118]   LOEC (21 d) 3.2 mg L
−1
 [174] 
    HPLC–MS/MS      (condition index)   
          NOEC (21 d) 10 mg L
−1
 [174] 
          (reproduction)   
          LOEC (21 d) >10 mg L
−1
 [174] 
          (reproduction)   
Metoprolol 83-43-2 STP influent Finland SPE- 3.8 980–1350 [16] Crustacean D. magna EC50  (48 h) >100 mg L
−1
 [65] 
    HPLC–MS/MS      (immobilization)   
  STP effluent    910–1070       
  Vantaa river    <3.8–116       
  water           
  Luhtajoki    38       
  river water           
Metoprolol  STP influent Sweden SPE-LC–MS/MS —† 160 [21] Algae D. subspicatus EC50 (growth 
inhibition) 
7.3 mg L−1 [65] 
  STP effluent    190       
  Höje river    30–70       
  water           
Metoprolol  STP influent Taiwan SPE- HPLC–
MS/MS 
—† 14–597 [87] Duckweed L. minor EC50 (7 d) (growth 
inhibition) 
>320 mg L−1 [65] 
  
 
 
Table 6 (Continued ) 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
  STP effluent    12–199       
        Fish O. mykiss LOEC (21 d) (liver 1 µg L
−1
 [97] 
          cytopathology)   
          LOEC (21 d) (gills 20 µg L
−1
 [97] 
          cytopathology)   
        Crustacean H. azteca LC50 (48 h) >100 mg L
−1
 [172] 
          (mortality)   
         C. dudia LC50 (48 h) 8.8 mg L
−1
 [172] 
          (mortality)   
         D. magna LC50 (48 h) 63.9 mg L
−1
 [172] 
          (mortality)   
        Fish O. latipes LC50 (48 h) >100 mg L
−1
 [172] 
          (mortality)   
        Algae D. subspicatus EC50 (48 h) (growth 7.9 mg L
−1
 [177] 
          inhibition)   
        Crustacean D. magna EC50  (48 h) 438 mg L
−1
 [175] 
          (immobilization)   
        Crustacean D. magna NOEC (9 d) (body 6.15 mg L
−1
 [176] 
          mass)   
          LOEC (9 d) (body 12.5 mg L
−1
 [176] 
          mass)   
          LOEC (9 d) 6.15 mg L
−1
 [176] 
          (reproduction)   
          LOEC (9 d) (heart 3.2 mg L
−1
 [176] 
          rate)   
Propranolol 525-66-6 STP influent Sweden SPE-LC–MS/MS —† 50 [21] Crustacean D. magna EC50  (48 h) 
(immobilization) 
7.5 mg L−1 [65] 
  STP effluent    30       
  Höje river    <1–10       
  water           
Propranolol  Hospital Taiwan SPE- 0.5 54 [47] Algae D. subspicatus EC50  (growth 5.8 mg L
−1
 [65] 
  effluent  HPLC–MS/MS      inhibition)   
  Pharmaceutical    ND       
  production           
  facility           
  effluent           
Propranolol  STP influent United Kingdom SPE- 10 60–119 [53] Duckweed L. minor EC50 (7 d) (growth 114 mg L
−1
 [65] 
    HPLC–MS/MS      inhibition)   
  STP effluent    195–373       
  Tyne river    35–107       
  water           
Propranolol  Hospital Spain SPE- 8 200–6500 [73] Crustacean T. platyurus LC50 (24 h) 10.31 mg L
−1
 [78] 
  effluent  HPLC–MS/MS      (mortality)   
Propranolol  Mankyung 
river water 
South Korea SPE-LC–MS/MS 10 ND–40.1 (±3) [92] Fish O. latipes LC50 (96 h) 
(mortality) 
11.40 mg L−1 [78] 
Propranolol  STP effluent United Kingdom SPE-  130–180 [94] Crustacean H. azteca LC50 (48 h) 29.8 mg L
−1
 [172] 
    HPLC–MS/MS      (mortality)   
  Surface water    <10–37       
          NOEC (27 d) 0.001 mg L
−1
 [172] 
          (reproduction)   
  
 
 
 
 
 
 
 
 
 
   LOEC (27 d) 
(reproduction) 
0.1 mg L−1 [172] 
 C. dudia LC50 (48 h) 0.8 mg L
−1
 [172] 
  (mortality)   
  NOEC (7 d) 0.125 mg L
−1
 [172] 
  (reproduction)   
  LOEC (7 d) 0.25 mg L
−1
 [172] 
  (reproduction)   
 D. magna LC50 (48 h) 1.6 mg L
−1
 [172] 
  (mortality)   
Fish O. latipes LC50 (48 h) 24.3 mg L
−1
 [172] 
  (mortality)   
Algae D. subspicatus EC50 (48 h) (growth 0.7 mg L
−1
 [175] 
  inhibition)   
Crustacean D. magna EC50  (48 h) 7.7 mg L
−1
 [175] 
  (immobilization)   
Duckweed L. minor EC50 (growth rate) 113 mg L
−1
 [175] 
Crustacean D. magna NOEC (9 d) (body 0.22 mg L−1 [176] 
  mass)   
  LOEC (9 d) (body 0.44 mg L
−1
 [176] 
  mass)   
  NOEC (9 d) 0.055 mg L
−1
 [176] 
  (reproduction)   
  LOEC (9 d) 0.11 mg L
−1
 [176] 
  (reproduction)   
  LOEC (9 d) (heart 0.055 mg L
−1
 [176] 
  rate)   
Sotalol 959-24-0 STP influent Finland SPE- 3.9 640–830 [16]      
    HPLC–MS/MS         
  STP effluent    160–300       
  Vantaa river    <3.9–52       
  water           
  Luhtajoki    37       
  river water           
Sotalol  Groundwater Germany SPE- 8.0 560 [26]      
    HPLC–MS/MS         
†—Data not available; ND—Not Detected; SPE—Solid Phase Extraction; HPLC–MS/MS—High Performance Liquid Chromatography with Tandem Mass Spectrometry Detection; LC–MS/MS—Liquid Chromatography with Tandem Mass  Spectrometry  
Detection. 
 4.7. Antidepressants 
 
Serotonin (or 5-hydroxytryptamine) is an important neuro- 
transmitter in hormonal and neuronal mechanisms. It participates in 
different regulatory and endocrine functions so that altered lev- els may 
cause changes in appetite, immune system, reproduction and other 
behavioural functions [10,35]. It is also important to lower 
vertebrates and invertebrates though being associated with different 
physiological mechanisms from those observed for mam- mals. In 
therapeutics, the selective serotonin reuptake inhibitors (SSRIs) 
fluoxetine, fluvoxamine, paroxetine and sertraline are the most widely 
used synthetic antidepressants. They act by inhibit- ing the reuptake of 
serotonin from the pre-synaptic nerve  cleft. It is thus obvious that 
from the presence of SSRIs in the envi- ronment (even at low 
concentrations (ng or µg L−1)), adverse effects on aquatic 
organisms could arise [177]. In fact, fluvox- amine at a 
concentration of 0.32 µg L−1 or fluoxetine at higher concentrations 
were capable of inducing spawning and oocyte maturation of zebra 
mussels (Dreissena polymorpha) [178]. On the contrary, a NOEC value 
of 0.47 µg L−1 was deduced for the ability of fluoxetine to reduce 
reproduction of the freshwater mudsnail Pota- mopyrgus antipodarum 
[179]. Japanese medaka were exposed to a range of fluoxetine from 0.1 
to 5 µg L−1 over four weeks, revealing that fecundity, egg fertilization 
and hatching success were unaf- fected. However, an increase in 
developmental abnormalities in fish embryos was observed and plasma 
estradiol concentrations were significantly raised in females [180]. 
Following an one-week exposure of western mosquitofish (Gambusia 
affinis) neonates to fluoxetine, a LC50 value of 546 µg L
−1 was obtained 
[181]. Although chronic exposure to concentrations from 0.05 to 5 µg 
L−1 increased lethargy, it did not affect survival, growth or sex ratio 
[181]. In turn, 
G. affinis exposed to 71 µg L−1 of fluoxetine from juvenile through 
adult life stages showed a delay in the development of mature sexual 
morphology in both male and female fish [181]. 
Another SSRI, sertraline, exhibits highly toxic properties. Fol- 
lowing a 96-h exposure of rainbow trout to sertraline, a LC50 of 
0.38 mg L−1 was deduced [182]. The same authors also found that 
those surviving fish exposed to 0.32 mg L−1 of sertraline for 72 h, died 
following irreparable physiological damage after being removed to 
control water. Fish exposed to higher concentrations of this 
pharmaceutical showed a decreased respiration and a loss of movement 
coordination. 
SSRIs were also tested on algae by evaluating the growth inhi- 
bition induced. Chronic toxicity tests proved that the organisms were 
sensitive with NOEC values below 1 mg L−1 [52]. C. vulgaris was 
shown to be the least sensitive species for all SSRIs tested [183]. On 
the contrary, Pseudokirchneriella subcapitata was the most sensitive 
species mainly regarding fluoxetine with a reported EC50 of 24 µg L
−1 
after 48 h [177,184] or 45 µg L−1 when the exposure time was 
increased to 96 h [183]. Cell deformities in these green algae were 
noticed with just 13.6 µg L−1 of fluoxetine. Similar EC50 values were 
determined for acute toxic effects caused by sertra- line on P. 
subcapitata and Scenedesmus acutus (12.1 and 99 µg L−1 respectively) 
[183]. By reducing the exposure time from 96 to 72 h, P. 
subcapitata showed an EC50 of 0.14 mg L
−1 [182]. Fluvox- amine 
gave rise to the highest EC50 values for all algae species tested 
(3563–10,208 µg L−1) [183]. An exposure of 96 h of the marine 
phytoplankton D. tertiolecta to fluoxetine showed an EC50 of 
169.81 µg L−1 [70], which is higher than growth rate EC50s reported 
previously to algae species. 
Tests performed on the invertebrates C. dubia, D. magna and on 
fathead minnow fish showed LC50 values of 234, 820 and 705 µg L
−1 
respectively, after 48 h of exposure to fluoxetine [184]. On the 
other hand, for paroxetine, D. magna showed an EC50 of 2.5 mg L
−1 
[185]. Regarding the invertebrates, fluoxetine may cause a stimu- lation 
of reproduction as is the case of C. dubia when exposed   to 
56 µg L−1 of this pharmaceutical [184]. This same effect was also 
found for D. magna after 30 days of exposure to a concentration of 36 
µg L−1 [116] which resulted in an increase in total number of offspring 
produced. Higher concentrations of fluoxetine were tested (e.g. 223 µg 
L−1) and proven to exert the opposite effect [184] in a similar way to 
that observed for sertraline, exhibiting an EC50 of 0.066 mg L
−1 and a 
LOEC of 0.1 mg L−1 [182]. A multi- generational study was performed 
by exposing D. magna and their newborns to fluoxetine [33]. The highest 
effects were found on the development of the embryos. The newborns 
length was affected (NOEC = 8.9 µg L−1 and LOEC = 31 µg L−1), what 
had consequences in their future reproduction, that was significantly 
reduced for a concentration of 31 µg L−1  [33]. The exposure of the 
invertebrate 
P. antipodarum to fluoxetine caused a decrease in reproduction, resulting 
in a NOEC of 13 µg L−1 and a LOEC of 69 µg L−1 [33]. In contrast, H. 
azteca reproduction was not affected by this SSRI, but a significant effect 
on growth was noticed, showing a NOEC and a LOEC of 33 and 100 µg 
L−1, respectively [33]. 
The behaviour of aquatic invertebrates was also shown to be 
affected by SSRIs as illustrated by the amphipod G. pulex in the 
presence of 10 and 100 ng L−1 of fluoxetine [76]. Fairy shrimps T. 
platyurus are more sensitive to sertraline compared to D. magna. For 
the former an EC50 of 0.6 mg L
−1 after 24 h was obtained and with D. 
magna corresponding EC50 values were 3.1 and 1.3 mg L
−1 after 24 and 
48 h, respectively [182]. Nematoceran flies Chirono- mus tentans and 
hydras H.  azteca  were  exposed  to  fluoxetine by sediments, showing 
growth inhibition with LOECs of 1.3 and 
5.6 mg kg−1 respectively [184]. However, hydras reproduction was 
stimulated for all concentrations tested (1.4–22.4 mg kg−1) as well as 
blackworms Lumbriculus variegatus when exposed to 0.94 and 
2.34 mg kg−1 of fluoxetine [179]. In C. tentans, this kind of exposure 
caused a reduction in emergence with a LOEC of 1.12 mg kg−1. On the 
other hand, Péry et al. [33] did not observed toxic effects on C. riparius 
growth, emergence and reproduction, even when exposed to 59.5 mg kg−1  
of fluoxetine. 
SSRIs contaminate different aquatic environments at concentra- tions 
in the order of ng L−1 (Table 7). Fluoxetine is a typical example, being 
detected in STP influents at concentrations of 0.4–18.7 ng L−1 and in 
effluents in the lower range of 0.12–8.4 ng L−1 [186–188]. This 
pharmaceutical was also detected in surface waters [23,188], 
groundwaters [28] and drinking water [32]. Other SSRIs, such as 
fluvoxamine, sertraline and paroxetine have also been detected in STP 
influents and effluents [186–188] as well as seawater (Nor- way) [187]. 
Antidepressants were detected at low concentrations (ng L−1) which 
may not represent isolated threats to non-target organisms when 
considering the respective contribution. However, since they exert 
similar effects and are present in the environ- ment as a mixture, it is 
possible that chronic exposure of aquatic organisms may induce 
toxicity. 
 
4.8. Antineoplasics 
 
Antineoplasic drugs are designed to kill cells that are prolif- erating 
excessively such as those found in pathological cancer conditions. 
Therefore, a similar effect on any other growing eukary- otic organisms is 
expected [189]. Pharmaceuticals belonging to this therapeutic class 
possess genotoxic, mutagenic, carcinogenic, ter- atogenic and fetotoxic 
properties and can constitute (in their native form) from 14 to 53% of 
the administered drug excreted in urine [108]. Cyclophosphamide and 
ifosfamide ecotoxicity predicted by ECOSAR have yielded EC50 values 
of 8.2 and 70 mg L−1 for algae and fish respectively, whereas the 
freshwater flea D. magna reg- istered a LC50 of 1795 mg L
−1 [108]. 
Toxicity tests performed on the algae P. subcapitata and the invertebrate  
D.  magna  showed that cyclophosphamide slightly increased the growth 
of the former (NOEC above 100 mg L−1) and reduced offspring number in 
the lat- 
  
 
 
Table 7 
Examples of concentrations (ng L−1 ) of antidepressants measured in different aquatic environments. 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
Amitriptyline —† STP influent 
STP effluent 
St. Lawrence 
Canada SPE-LC–MS/MS 0.077 17.6 (±0.8)–20.8 
(±1.2) 
15.6 (±0.8)–21.0 
(±1.5) 
0.87 (±0.07)–3.7 
[188]      
 
Nortriptyline* 
 
—† 
River water 
STP influent 
 
Canada 
 
SPE-LC–MS/MS 
 
0.057 
(±0.2) 
3.1 (±0.1)–4.5 
 
[188] 
     
   
STP effluent 
 
St. Lawrence 
   (±0.4) 
1.5 (±0.1)–3.8 
(±0.4) 
0.41 
      
 
 
Citalopram 
 
 
59729-33-8 
River water 
 
STP influent 
 
 
Norway 
 
 
SPE-HPLC–MS 
 
 
0.16 
(±0.02)–0.73 
(±0.06) 
13.0–612 
 
 
[186] 
     
  STP effluent    9.2–382       
Citalopram  STP influent Norway HF-LPME- 0.017 62.9 [187]      
   
 
STP effluent 
 HPLC–MS  (±30.7)–303.6 
(±4.3) 
21.9 
      
 
 
Citalopram 
  
 
STP influent 
 
 
Canada 
 
 
SPE-LC–MS/MS 
 
 
0.077 
(±13.5)–238.4 
(±23.6) 
52.2 (±3.7)–52.7 
 
 
[188] 
     
   
STP effluent 
 
St. Lawrence 
   (±4.9) 
46.8 (±1.2)–57.8 
(±0.3) 
3.4 (±0.2)–11.5 
      
 
Fluoxetine 
 
54910-89-3 
River water 
Surface water 
 
USA 
 
SPE-LC–MS 
 
18 
(±0.8) 
12 
 
[23] 
 
Amphipod 
 
H. azteca 
 
LOEC (28 d) (growth) 100 µg L−1 
 
[33] 
Fluoxetine  Groundwater USA SPE-HPLC–MS 18 56 [28]   NOEC (28 d) (growth) 33 µg L
−1
 [33] 
Fluoxetine  Drinking USA SPE-LC–MS/MS 0.50 0.64 [32] Crustacean D. magna NOEC (21 d) 8.9 µg L
−1
 [33] 
  water        (newbornes lenght)   
Fluoxetine  STP effluent South Korea SPE-LC–MS/MS 1.0 1.7 [90]   LOEC (21 d) 31 µg L
−1
 [33] 
          (newbornes lenght)   
  Surface water    ND       
Fluoxetine  STP influent Norway SPE-HPLC–MS 0.12 0.4–2.4 [186] Freshwater snail P. antipodarum NOEC (reproduction) 13 µg L
−1
 [33] 
  STP effluent    <0.12–1.3       
Fluoxetine 
 
 
 
Fluoxetine 
 STP influent 
STP effluent 
STP influent 
Norway 
 
 
 
Canada 
HF-LPME- 
HPLC–MS 
 
 
SPE-LC–MS/MS 
0.15 
 
 
 
0.05 
1.1 (±22.9)–18.7 
(±0.9) 
0.6 (±20.0)–8.4 
(±22.9) 
3.1 (±0.3)–3.5 
[187] 
 
 
 
[188] 
 
 
 
 
Crustacean 
 
 
 
 
Gammarus 
LOEC (reproduction) 
 
 
 
LOEC (behaviour) 
69 µg L−1 
 
 
 
100 ng L−1 
[33] 
 
 
 
[76] 
   
STP effluent 
 
St. Lawrence 
   (±0.3) 
2.0 (±0.1)–3.7 
(±0.1) 
0.42 (±0.01)–1.3 
  pulex    
  River water    (±0.1)   
Algae 
 
Dunaliella 
 
EC50 (96 h) (growth 169.81 µg L
−1
 
 
[70] 
         tertiolecta inhibition)   
         P. subcapitata EC50  (120 h) (growth) 24 µg L
−1
 [17]7 
          LOEC (growth) 13.6 µg L
−1
 [177] 
        Crustacean C. dubia LC50 (48 h) 234 µg L
−1
 [177] 
          NOEC 56 µg L
−1
 [177] 
          LOEC 112 µg L
−1
 [177] 
  
 
Table 7 (Continued ) 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
         D. magna LC50 (48 h) 820 µg L−1 [177] 
        Fish P. pimelas LC50 (48 h) 705 µg L
−1
 [177] 
        Midge C. tentans LC50 (10 d) 15.2 mg kg
−1
 [177] 
          LOEC (10 d) (growth) 1.3 mg kg
−1
 [177] 
        Amphipod H. azteca LOEC (growth) 5.4 mg kg
−1
 [177] 
        Freshwater snail P. antipodarum EC10 (56 d) (n
◦
 0.81 µg L
−1
 [179] 
          embryos whitout   
          shell)   
          NOEC (56 d) (n
◦
 0.47 µg L−1 [179] 
          embryos whitout   
          shell)   
        Midge C. riparius LOEC (28 d) 1.12 mg kg
−1
 [179] 
          (emergence)   
        Mosquitofish Gambusia LC50 (7 d) (lethality) 546 µg L
−1
 [181] 
         affinis    
        Algae P. subscapitata IC50  (96 h) (growth 44.99 µg L
−1
 [183] 
          inhibition)   
         S. acutus IC50  (96 h) (growth 91.23 µg L
−1
 [183] 
          inhibition)   
         S. quadricauda IC50  (96 h) (growth 212.98 µg L
−1
 [183] 
          inhibition)   
         C. vulgaris IC50  (96 h) (growth 4339.25 µg L
−1
 [183] 
          inhibition)   
        Algae P. subscapitata EC50  (120 h) (growth) 39 µg L
−1
 [184] 
        Crustacean C. dubia LC50 (48 h) (survival) 234 µg L
−1
 [184] 
         D. magna LC50 (48 h) (survival) 820 µg L
−1
 [184] 
        Fish P. promelas LC50 (48 h) (survival) 705 µg L
−1
 [184] 
        Midge C. tentans LC50 (10 d) (survival) 15.2 mg kg
−1
 [184] 
          LOEC (10 d) (growth) 1.3 mg kg
−1
 [184] 
        Amphipod H. azteca LOEC (10 d) (growth) 5.6 mg kg
−1
 [184] 
Norfluoxetine* 83891-03-6 Drinking USA SPE-LC–MS/MS 0.50 0.77 [32]      
  water           
Norfluoxetine*  STP influent 
 
STP effluent 
Norway HF-LPME- 
HPLC–MS 
0.16 
 
0.54 (LOQ) 
0.7 (±13.1)–9.3 
(±4.6) 
<0.54–2.4 
[187]      
 
Norfluoxetine* 
  
STP influent 
 
Canada 
 
SPE-LC–MS/MS 
 
0.087 
(±14.5) 
1.8 (±0.3)–4.2 
 
[188] 
     
   
STP effluent 
 
St. Lawrence 
   (±0.5) 
1.7 (±0.1)–1.8 
(±0.3) 
1.2 (±0.1)–1.3 
      
 
Fluvoxamine 
 
54739-18-3 
River water 
STP influent 
 
Norway 
 
SPE-HPLC–MS 
 
0.15 
(±0.1) 
0.4–3.9 
 
[186] 
 
Algae 
 
P. subscapitata 
 
IC50  (96 h) (growth 4002.88 µg L
−1
 
 
[183] 
          inhibition)   
  STP effluent    <0.15–0.8       
Fluvoxamine  STP influent 
 
STP effluent 
Norway HF-LPME- 
HPLC–MS 
0.129 
 
0.379 (LOQ) 
0.8 (±38.2)–1.7 
(±18.6) 
<0.379–0.8 
[187]  S. acutus IC50 (96 h) (growth 
inhibition) 
3620.24 µg L−1 [183] 
   
Seawater 
   (±38.2) 
0.5 (±0.5)–0.8 
(±0.3) 
    
 
S. quadricauda 
 
 
 
IC50  (96 h) (growth 
 
 
 
3563.34 µg L−1 
 
 
 
[183] 
          inhibition)   
C. vulgaris IC50 (96 h) (growth 
inhibition) 
10,208.47 µg L−1[183] 
  
 
 
 
 
Paroxetine 
 
61869-08-7 
 
STP influent 
 
Norway 
 
SPE-HPLC–MS 
 
0.12 
 
0.6–12.3 
 
[186] 
 
Crustacean 
 
D. magna 
 
EC50  (48 h) 
(immobilization) 
2.5 mg L−1 
 
[185] 
  STP effluent    0.5–1.6       
Paroxetine 
 
 
 
 
 
 
Paroxetine 
 STP influent 
STP effluent 
Seawater 
STP influent 
Norway 
 
 
 
 
 
 
Canada 
HF-LPME- 
HPLC–MS 
 
 
 
 
 
SPE-LC–MS/MS 
0.053 
 
 
 
 
 
 
0.096 
2.9 (±19.0)–12.9 
(±29.4) 
1.0 (±15.7)–11.7 
(±36.8) 
0.6 (±0.4)–1.4 
(±0.4) 
4.6 (±0.3)–5.3 
[187] 
 
 
 
 
 
 
[188] 
     
   
STP effluent 
 
St. Lawrence 
   (±0.2) 
4.3 (±0.2)–5.2 
(±0.5) 
1.3 (±0.1)–3.0 
      
 
Sertraline 
 
79617-96-2 
River water 
STP influent 
 
Norway 
 
SPE-HPLC–MS 
 
0.29 
(±0.1) 
1.8–2.5 
 
[186] 
 
Bacteria 
 
V. fischeri 
 
EC50  (30 min) 10.72 mg L
−1
 
 
[182] 
          (inhibition)   
  STP effluent    0.9–2.0       
Sertraline  STP influent 
STP effluent 
Seawater 
Norway HF-LPME- 
HPLC–MS 
0.16 
 
0.52 (LOQ) 
8.4 (±4.5)–19.8 
(±10.8) 
3.7 (±16.3)–14.6 
(±4.2) 
<0.52 
[187]   NOEC (30 min) 
(inhibition) 
2.25 mg L−1 [182] 
Sertraline  STP influent 
STP effluent 
St. Lawrence 
Canada SPE-LC–MS/MS 0.048 6.0 (±0.4)–6.1 
(±0.3) 
5.1 (±0.3)–5.8 
(±0.8) 
0.84 (±0.09)–2.4 
[188]   LOEC (30 min) 
(inhibition) 
4.5 mg L−1 [182] 
  River water    (±0.1)   
Algae 
 
P. subcapitata 
 
EC50  (72 h) 0.14 mg L
−1
 
 
[182] 
          (inhibition)   
          NOEC (72 h) 0.05 mg L
−1
 [182] 
          (inhibition)   
          LOEC (72 h) 0.075 mg L
−1
 [182] 
          (inhibition)   
 Shrimp T. platyurus LC50  (24 h) (lethality) 0.6 mg L
−1
 [182] 
  NOEC (24 h) 0.4 mg L
−1
 [182] 
  (lethality)   
  LOEC (24 h) (lethality) 0.6 mg L
−1
 [182] 
Crustacean D. magna EC50  (48 h) 1.3 mg L
−1
 [182] 
  (immobilization)   
  NOEC (48 h) 0.10 mg L
−1
 [182] 
  (immobilization)   
  LOEC (48 h) 0.18 mg L
−1
 [182] 
  (immobilization)   
  EC50  (21 d) 0.066 mg L
−1
 [182] 
  (reproduction)   
  NOEC (21 d) 0.032 mg L
−1
 [182] 
  (reproduction)   
  LOEC (21 d) 0.1 mg L
−1
 [182] 
  (reproduction)   
  LC50  (21 d) (lethality) 0.12 mg L
−1
 [182] 
  NOEC (21 d) 0.032 mg L
−1
 [182] 
  (lethality)   
  LOEC (21 d) (lethality) 0.1 mg L
−1
 [182] 
Fish O. mykiss LC50  (96 h) (lethality) 0.38 mg L
−1
 [182] 
  NOEC (96 h) 0.1 mg L
−1
 [182] 
  (lethality)   
  
 
 
 
 
 
 
 
 
Table 7 (Continued ) 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
          NOEC (96 h) 0.32 mg L−1 [182] 
          (lethality)   
        Algae P. subcapitata IC50  (96 h) (growth 12.10 µg L
−1
 [183] 
          inhibition)   
         S. acutus IC50  (96 h) (growth 98.92 µg L
−1
 [183] 
          inhibition)   
         S. quadricauda IC50  (96 h) (growth 317.02 µg L
−1
 [183] 
          inhibition)   
         C. vulgaris IC50  (96 h) (growth 763.66 µg L
−1
 [183] 
          inhibition)   
Desmethylsertraline* 87857-41-8 STP influent 
STP effluent 
St. Lawrence 
Canada SPE-LC–MS/MS 0.072 4.2 (±0.6)–5.0 
(±0.8) 
3.6 (±0.3)–4.7 
(±0.5) 
2.3 (±0.1)–4.5 
[188]      
 
Venlafaxine 
 
99300-78-4 
River water 
STP influent 
 
Canada 
 
SPE-LC–MS/MS 
 
0.10 
(±0.4) 
195.7 
 
[188] 
     
   
 
STP effluent 
   (±25.3)–213.0 
(±8.2) 
175.9 
      
   
 
St. Lawrence 
   (±12.7)–214.6 
(±3.6) 
12.9 (±0.1)–45.9 
      
 
Desmethylvenlafaxine* 
 
—† 
River water 
STP influent 
 
Canada 
 
SPE-LC–MS/MS 
 
0.097 
(±2.0) 
274.3 
 
[188] 
     
   
 
STP effluent 
   (±26.5)–345.9 
(±19.8) 
222.5 
      
   
 
St. Lawrence 
   (±16.8)–330.0 
(±9.8) 
21.0 (±0.5)–68.7 
      
  River water    (±3.1)       
*—Metabolite; ND—Not Detected; †—Data not available; SPE—Solid Phase Extraction; HF-LPME—Hollow Fibre Supported Liquid Phase Microextraction; HPLC–MS—High Performance Liquid Chromatography with Mass Spectrometry Detection; LC–MS—
Liquid Chromatography with Mass Spectrometry Detection; LC–MS/MS—Liquid Chromatography with Tandem Mass Spectrometry Detection. 
  
 
 
 
 
 
Table 8 
Examples of concentrations (ng L−1 ) of antineoplasic drugs measured in different aquatic environments. 
 
Compound CAS number Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
Ref. Taxon Species Toxicological 
endpoint 
Ecotoxicity 
data 
Ref. 
Cyclophosphamide 50-18-0 Somes river 
water 
Romania SPE-GC–MS 30 (LOQ) <30–64.8 (±8.0) [20] Algae P. subcapitata EC50 (72 h) (growth 
inhibition) 
>100 mg L−1 [190] 
Cyclophosphamide  STP effluent Italy SPE- 1.9 (LOQ) <1.9–9.0 [118]   NOEC (72 h) (growth >100 mg L
−1
 [190] 
    HPLC–MS/MS      inhibition)   
Cyclophosphamide  STP influent —† SPE-GC–MS 6 <6–143 [192] Crustacean D. magna EC50  (21 d) 
(reproduction) 
>100 mg L−1 [190] 
  STP effluent    6–15       
  Hospital    19–4486       
  effluent           
Cyclophosphamide  STP influent Switzerland SPE-LC–MS/MS 0.3 2.0–6 [193]   LOEC (21 d) 100 mg L
−1
 [190] 
          (reproduction)   
  STP effluent    2.1–4       
          NOEC (21 d) 56 mg L
−1
 [190] 
          (reproduction)   
Ifosfamide 84711-20-6 STP influent Switzerland SPE-LC–MS/MS 0.3 <0.3–5 [193]      
  STP effluent    1.7–6       
Methotrexate 59-05-2 STP effluent Italy SPE- 0.83 (LOQ) <0.83–12.6 [118] Bacteria V. fischeri EC50  (30 min) 1220 mg L
−1
 [83] 
    HPLC–MS/MS         
        Algae Scenedesmus EC50  (72 h) 260 mg L
−1
 [83] 
         subspicatus    
        Crustacean D. magna EC50 (immobilization) >1000 mg L
−1
 [83] 
        Ciliates Tetrahymena EC50 (48 h) (growth 45 mg L
−1
 [83] 
         pyriformis inhibition)   
        Fish D. rerio LC50 (48 h) 85 mg L
−1
 [83] 
Tamoxifen 74899-71-1 STP influent United Kingdom SPE- 10 143–215 [53] Rotifer B. calyciflorus LC50 (24 h) 0.97 mg L
−1
 [191] 
    HPLC–MS/MS      (mortality)   
  STP effluent    146–369       
  Tyne river    27–212       
  water           
Tamoxifen  STP effluent United Kingdom SPE- 10 <10 [94]   EC50  (48 h) 0.25 mg L
−1
 [191] 
    HPLC–MS/MS      (population growth   
          inhibition)   
  Surface water    <10       
Tamoxifen  STP influent United Kingdom SPE-LC–MS/MS 0.003 0.2–15 [194] Crustacean T. platyurus LC50 (24 h) 0.40 mg L
−1
 [191] 
          (mortality)   
  STP effluent    0.2–0.7       
         D. magna EC50  (24 h) 1.53 mg L
−1
 [191] 
          (immobilization)   
         C. dubia EC50 (7 d) (population 
growth inhibition) 
8.1 × 10−4 mg L
−[1191] 
†—Data not available; SPE—Solid Phase Extraction; GC–MS—Gas Chromatography with Mass Spectrometry Detection; HPLC–MS/MS—High Performance Liquid Chromatography with Tandem Mass Spectrometry Detection; LC–MS/MS—Liquid 
Chromatography with Tandem Mass Spectrometry  Detection. 
 ter at all tested concentrations of the drug (10–100 mg L−1), with a 
NOEC of 56 mg L−1 [190]. Methotrexate revealed teratogenicity for 
fish embryos with an EC50 of 85 mg L
−1 after 48 h of exposure [83] and 
acute effects in the ciliate Tetrahymena pyriformis with an EC50 for 48 h 
of 45 mg L−1 [83]. Acute and chronic toxicity of tamox- ifen and its 
photoproducts was studied by DellaGreca et al. [191], showing that both 
the active pharmaceutical and its photoproducts affected the rotifer B. 
calyciflorus and crustacean T. platyurus with LC50 values ranging from 
0.95 to 1.31 mg L−1 and 0.40 to 1.59 mg L−1 respectively. In chronic 
toxicity tests, C. dubia proved the most sen- sitive organism. An EC50 
value of 0.81 µg L−1 for tamoxifen and EC50 values ranging from 0.41 to 
2.8 µg L−1 for its photoproducts, rela- tive to population growth 
inhibition, were found after a 7-day trial [191]. 
The antineoplasic drug cyclophosphamide  has  been  detected in 
hospital effluents at  concentrations  ranging  from  19 ng L−1 to 4.5 µg 
L−1 [192], in STP influents [192,193] and effluents [118,192,193] and in 
surface waters [20] (Table 8). Other antineo- plasic pharmaceuticals 
detected to date have been in the order of ng L−1. However, as chronic 
toxicity data is very sparse, further studies are required to elucidate 
the potential effect of life-cycle exposure to these compounds in aquatic   
organisms. 
 
4.9. X-ray contrast media 
 
Contrast media are used as diagnostic tools for capturing detailed 
X-ray images of soft tissues. Iodinated X-ray contrast media are 
highly hydrophilic substances that are widely used and eliminated 
almost non-metabolised. STP removal processes are usually 
ineffective and for this reason they persist for a long time in the 
environment. As X-ray contrast media do not show biolog- ical 
activity, their presence might not represent a threat to public health 
[35,195,196]. Toxicity tests have shown that iopromide or its main 
metabolite do not have a toxic effect in luminescent bacteria, algae 
(Scenedesmus subspicatus), daphnids or fish (D. rerio, Leuciscus idus) 
even at concentrations as high as 1 g L−1 [196,197]. Contam- ination 
by X-ray contrast media has been reported in different aquatic 
environments (Table 9). Media have been detected in STP influents and 
effluents [198–201], surface waters [199,201–203], groundwaters 
[26,199,200] and even drinking water [200,202,203] at concentrations 
that can reach few µg L−1. Although accepting that X-ray contrast 
media do not exhibit toxic effects at high con- centration levels, 
additional studies should be undertaken with a view to evaluating 
chronic effects, due to continuous exposure of aquatic organisms to 
these pharmaceuticals. 
 
4.10. Mixture effects 
 
Presently environmental risk assessment of pharmaceuticals is based 
on single compounds ecotoxicity studies. However, pharma- ceuticals do 
not occur alone in the environment, but as a mixture of different active 
substances, their metabolites and transformation products [23,205,206]. 
Ecotoxicological data showed that mixtures might have different effects 
than single compounds [65,70,207], but in general knowledge about 
the toxicity of the mixture of active substances is still sparse. There 
are some examples of toxi- city studies in literature showing that 
mixture of pharmaceuticals at environmentally relevant concentrations 
may exhibit additive effects [70]. In some cases, lower levels than 
expected may lead to toxic effects when in the presence of a mixture 
of active sub- stances [70]. For instance, Cleuvers [65] showed that a 
mixture of diclofenac and ibuprofen had a stronger toxicity than 
predicted in 
D. magna, and when the author added more two NSAIDs (naproxen and 
acetylsalicylic acid) to the last two, a considerable toxicity on 
Daphnia was also reported, even at concentrations at which 
the single NSAIDs do not exhibit effects [95]. The exposure of the 
cnidarian H. attenuata to a mixture of eleven pharmaceuticals, 
belonging to different therapeutic classes, showed also sub-lethal 
effects for environmentally relevant concentrations (µg–ng L−1) 
[207]. Acute exposure of D. magna to a mixture of 36 µg L−1 of 
fluoxetine and 100 µg L−1 of clofibric acid caused a significant mor- tality 
and malformation, while there are no apparent effects for the same 
concentrations of individual pharmaceuticals [116]. The mixture of 
trimethoprim with sulfamethoxazole and sulfadiazine increased 
significantly the growth inhibition of the algae S. capri- cornutum 
[131]. On the other hand, the exposure of H. azteca to a mixture of 
seven pharmaceuticals did not reveal significant effects on their survival, 
mating, body size or reproduction, but there was a slight increase in the 
number of males [208]. Identical results were observed for fish. 
Apparently, a life-cycle exposure of fathead min- nows to a mixture of 
six pharmaceuticals, in the order of ng L−1, did not affect their 
survival, growth or egg production, however it increased the number of 
deformities in their offspring [209]. The examples here highlighted 
showed that the simultaneous presence of several pharmaceuticals in the 
environment might result in a greater toxicity to non-target organisms 
than the predicted one for individual active substances. However, more 
ecotoxicological studies should be done to evaluate the impact of 
different mixtures of pharmaceuticals in non-target organisms, once that 
most of the published studies are focused on mixture of NSAIDs, 
antibiotics and blood lipid lowering agents. 
 
 
5. Pharmaceuticals and legislation: what does legislation say? 
 
Every day an increasing number of pharmaceuticals reach the 
environment all over the world. However, there is a gap in legisla- tion 
regarding environmental contamination by pharmaceuticals. This 
probably arises because available data is insufficient to quan- tify a 
precise contamination profile. Abundant conclusive studies concerning 
chronic toxicity are also lacking so that it becomes impossible to 
infer the risks of long-term exposure of pharmaceuti- cals and their 
metabolites on fauna and flora. In this section, EU and US laws concerning 
the necessity of environmental risk assessment studies to obtain a 
marketing authorisation for pharmaceuticals is approached. 
The European Union Directive 92/18/EEC [210] introduced for the 
first time, the requirement for an environmental risk assess- ment, as a 
prerequisite to obtain marketing authorization for veterinary 
pharmaceuticals. For this purpose, the European Agency for the Evaluation 
of Medicinal Products (EMEA) published a “Note for Guidance” [211] 
where guidelines to assess the environmental risk of veterinary 
medicinal products are established. The Euro- pean Commission 
extended its concerns to pharmaceuticals for human use by publishing 
Directive 2001/83/EC which was subse- quently amended by Directive 
2004/27/EC [212]. These directives established that marketing 
authorization for new medical prod- ucts for human use should be 
accompanied by an environmental risk assessment, whose guidelines 
were set out by EMEA [213]. Nevertheless, the environmental impact 
does not provide suffi- cient grounds for a refusal. Environmental risk 
assessment of both veterinary and human pharmaceuticals is assessed 
in a step-wise approach, divided into two phases. In Phase I, 
environmental expo- sure to the pharmaceutical or its metabolites is 
estimated. Phase II comprises its fate and effects in the environment. 
For this reason, Phase II is sub-divided into two parts: Tier A, in which 
possible fate and effects of the pharmaceutical and/or its major 
metabolites are evaluated; and Tier B, which focuses on the effects on 
fauna and flora within environmental compartments that are likely to 
be affected [211,213]. However, medicinal products for human use 
  
 
 
Table 9 
Examples of concentrations (ng L−1 ) of X-ray contrast media measured in different aquatic environments. 
 
Compound    CAS number    Sample Country Analytical 
procedure 
LOD (ng L−1 ) Concentration 
reported (ng L−1 ) 
 
Ref. Taxon Species Toxicological 
endpoint 
 
Ecotoxicity 
data 
 
Ref. 
Diatrizoate     131-49-7 STP effluent Germany SPE-LC–MS/MS 50 (LOQ STP effluent) 250 [199] 
Surface water   10 (LOQ surface water; groundwater)    <10–8700 
Groundwater 30 
Diatrizoate Surface water Germany SPE-HPLC–MS —† 2000 [203] 
Drinking water    1200 
Diatrizoate STP effluent Germany SPE-LC–MS/MS 50 (LOQ STP effluenT) 1140 [204] 
Rhine river 
water 
10 (LOQ surface and drinking water)      110–140 
Drinking water 60 
Iohexol 66108-95-0     STP influent Australia DI-LC–MS/MS 800 2800–4760 [201] 
STP effluent <800 
Iohexol Danube river 
water 
Germany SPE- HPLC–
MS/MS 
40 40–86 [202] 
Iomeprol 78649-41-9      STP effluent Germany SPE-LC–MS/MS 50 (LOQ STP effluent) 370  [199] 
Surface water   10 (LOQ surface water)  10–890 
Iomeprol STP influent Australia DI-LC–MS/MS 730 <730 [201] 
STP effluent <730 
Iomeprol Danube river 
water 
Germany SPE- HPLC–
MS/MS 
40 100–160 [202] 
Iopamidol      60166-93-0     Groundwater Germany SPE- 
HPLC–MS/MS 
14 300 [26] 
Iopamidol STP effluent Germany SPE-LC–MS/MS 50 (LOQ STP effluent) 660 [199] 
Surface water   10 (LOQ surface water; groundwater)     170–2800 
Groundwater 160 
Iopamidol STP influent Australia DI-LC–MS/MS 220 400–620 [201] 
STP effluent <220 
Iopamidol Danube river 
water 
Germany SPE- HPLC–
MS/MS 
40 210 [202] 
Iopamidol STP effluent Germany SPE-LC–MS/MS 50 (LOQ STP effluent) 590 [204] 
Rhine river 
water 
10 (LOQ surface and drinking water)      180–300 
Drinking water 70 
Iopromide    73334-07-3    STP effluent South Korea SPE-LC–MS/MS 1.0 1170–4030 [90] Crustacean  D. magna EC50 (48 h) 
(immobilization) 
>1 g L−1 [15]7 
Surface water 20–361 
Drinking water <1.0 
Iopromide STP influent Spain SPE-LC–MS/MS 6.7 6600 [198]    Fish D. rerio NOEC (28 d) 
(hatchability, 
post-hatch survival, 
body length, weight) 
 
 
>100 mg L−1   [157] 
STP effluent 9300 
Iopromide STP effluent Germany SPE-LC–MS/MS 50 (LOQ STP effluent) 4400 [199]    Bacteria V. fischeri EC50  (30 min) 
(luminescence) 
 
>10.0 g L−1 [158] 
Surface water 10 (LOQ surface water; groundwater)    11–910 
Groundwater  <10 
Iopromide STP influent USA SPE-LC–MS/MS 0.577 ND–17 [200] P. putida EC10 (16 h) (growth 
inhibition) 
 
 
>10.0 g L−1 [158] 
STP effluent 4.6 
Ohio river 
water 
2.2 
Drinking water 4.6 
 
  
 
only require Phase II studies if the predicted environmental con- centration in 
surface water is equal to or above 0.01 µg L−1 [213]. 
In the US, issues concerning pharmaceuticals in the environ- ment are 
regulated by the U.S. Food and Drug Administration (FDA). This institution 
requires environmental assessments to obtain mar- keting authorisations 
which are specified in the “Guidance for Industry—Environmental 
Assessment of Human Drug and Biologic Applications” [214]. However, 
an environmental assessment is required only if the estimated 
environmental concentration of the pharmaceutical at the point of the 
entry is above 1 µg L−1 [214]. As EMEA, the FDA also requires 
environmental assessments for vet- erinary medicinal products, using a 
tiered approach. With a view to harmonising the guidelines that govern 
these environmental impact assessments, the EU, US and Japan 
elaborated two guide- lines: “Environmental Impact Assessment (EIAs) 
for Veterinary Medicinal Products (VMPs)—Phase I” [215] and 
“Environmental Impact Assessment for Veterinary Medicinal Products—
Phase II Guidance” [216] so that environmental fate and toxicity data 
obtained could be used to obtain marketing authorisation in all these 
regions. 
 
 
6. Conclusions 
 
Today, the presence of pharmaceuticals in the environment is being 
reported worldwide. Furthermore, new data on the sources, fate and 
effects of pharmaceuticals in the environment, seems to indicate the 
possibility of a negative impact on different ecosys- tems and imply a 
threat to public health. For this assumption, data from acute and 
chronic ecotoxicity tests on species belong- ing to different trophic 
levels such as bacteria, algae, crustaceans and fish among others, is 
relevant to illustrate the several adverse effects that environmental 
exposure to measured concentrations of these contaminants can have. 
On literature, the principal toxico- logical endpoints/studies that are 
described are growth, survival, reproduction and immobilization of 
species, comparatively to transgenerational and population level studies 
that are still sparse. This demonstrates the lack of data relatively to 
long-term expo- sure of non-target organisms and principally how a 
continuous exposure, during several generations, may affect a whole 
popu- lation. To our knowledge, just one work followed the impact  of 
a pharmaceutical in a fish population throughout seven years, 
showing how ethinylestradiol negatively affect the fish popula- tion, 
leaving them near of the extinction. In the near future, the evaluation 
of chronic toxicity effects should be set out as a prior- ity for the 
scientific community since simultaneous exposure to pharmaceuticals, 
metabolites and transformation products of sev- eral therapeutic classes 
are unknown and whose probable effects on subsequent generations 
should be assumed. Another example of missing data is what occurs with 
statins. Nowadays, they are the blood lipid lowering agents most used all 
over the world, although toxicity data relatively to them is almost 
non-existent and lim- ited to the active substances simvastatin and 
atorvastatin. It is also important to assess the presence of 
pharmaceuticals and/or their metabolites and transformation products in 
several environmental compartments in different countries with a view to 
gaining reliable knowledge of the contamination levels. Only with further 
available information will be easier to improve existing legislation in 
order to protect humans, animals and ecosystems from the threat posed 
by the presence of pharmaceuticals in the environment. 
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